diabglym

# CILROOT-XL25 **Cilnidipine 10 mg & Metoprolol Succinate Extended Release 25 mg Tablets** **Division: DIABGLYM** ## Composition Each extended-release tablet contains: * Cilnidipine IP — 10 mg * Metoprolol Succinate Extended Release IP equivalent to Metoprolol — 25 mg * Excipients — q.s. * Colour: Approved colour used **Dosage Form:** Extended-release oral tablet ## Product Description CILROOT-XL25 is a balanced antihypertensive combination of **Cilnidipine 10 mg and Metoprolol Succinate Extended Release 25 mg**, formulated for the management of hypertension and cardiovascular conditions requiring both blood pressure and heart-rate control. Cilnidipine provides sustained arterial vasodilation through dual L-type and N-type calcium channel blockade, while Metoprolol Succinate ER provides sustained beta-1 selective blockade. Together, they offer complementary mechanisms for blood pressure control and reduction of cardiac workload. CILROOT-XL25 may be considered for patients with hypertension associated with tachycardia, coronary artery disease, diabetes, metabolic syndrome, or those requiring combination antihypertensive therapy, as determined by the treating physician. ## Technical Knowledge **Cilnidipine** blocks L-type calcium channels in vascular smooth muscle and N-type calcium channels associated with sympathetic nerve terminals. This promotes vasodilation, reduces peripheral vascular resistance, and helps modulate sympathetic activity. **Metoprolol Succinate ER** selectively blocks beta-1 adrenergic receptors, reducing sympathetic stimulation, heart rate, myocardial contractility, cardiac output, and renin release. The extended-release formulation provides sustained therapeutic activity. The combination therefore addresses both **vascular resistance and cardiac sympathetic activity**, providing complementary antihypertensive action. ## Mechanism of Action **Cilnidipine:** Blocks L-type and N-type calcium channels → vascular relaxation → reduced peripheral vascular resistance → blood pressure reduction. **Metoprolol Succinate ER:** Selective beta-1 blockade → reduced heart rate and myocardial contractility → reduced cardiac workload and myocardial oxygen demand. ## Key Benefits * Effective reduction of elevated blood pressure * Dual-mechanism antihypertensive therapy * Sustained blood pressure control * Helps control elevated heart rate * Reduces cardiac workload * Reduces myocardial oxygen demand * Modulates sympathetic activity * Convenient combination therapy * Suitable for long-term cardiovascular management under medical supervision ## Clinical Applications CILROOT-XL25 may be prescribed for: * Essential hypertension * Hypertension with tachycardia * Hypertension with coronary artery disease * Hypertension associated with diabetes * Cardiovascular risk management * Patients requiring combination antihypertensive therapy ## Key Facts * **Cilnidipine 10 mg** provides vascular calcium-channel blockade. * **Metoprolol Succinate ER 25 mg** provides sustained beta-1 selective blockade. * Combines vascular and cardiac mechanisms. * Designed for sustained cardiovascular control. * Suitable for individualized antihypertensive therapy under physician supervision. * Quality-assured pharmaceutical formulation. ## PCD Pharma Franchise Opportunity CILROOT-XL25 is a suitable addition to **PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise** portfolios across India. The growing demand for combination antihypertensive therapies creates significant prescription and market potential. ### Why Choose CILROOT-XL25? * Strong therapeutic segment * Combination formulation * Broad physician potential * Competitive commercial opportunity * Attractive monopoly franchise potential * Promotional support * Visual aid and marketing support * Consistent product quality * Potential for repeat business ## Third Party Manufacturing **Chemsroot Pharmaceutical** offers Third Party Manufacturing of Cilnidipine 10 mg and Metoprolol Succinate Extended Release 25 mg Tablets for pharmaceutical companies, marketers, exporters, and franchise businesses. ### Manufacturing Services * Private label manufacturing * Contract manufacturing * Custom brand manufacturing * Loan license manufacturing * GMP-compliant production * Batch manufacturing documentation * Product registration support * Customized packaging and artwork * Monopoly franchise packaging * Bulk manufacturing capability ### Manufacturing Features * Pharmaceutical-grade raw materials * In-process quality control * Finished product testing * Stability-oriented extended-release formulation * Controlled-release manufacturing technology * Blister and Alu-Alu packaging options **CILROOT-XL25 from DIABGLYM** combines sustained antihypertensive action, heart-rate control, and complementary cardiovascular therapy, making it a valuable formulation for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients.

CILROOT-50 Cilnidipine 10 mg and Metoprolol Succinate Extended Release 50 mg Tablets Division: DIABGLYM Composition Each extended-release tablet contains: Cilnidipine IP — 10 mg Metoprolol Succinate Extended Release IP equivalent to Metoprolol — 50 mg Excipients — q.s. Colour: Approved colour used Dosage form: Extended-release oral tablet Product Description CILROOT-50 is a scientifically balanced antihypertensive combination of Cilnidipine 10 mg and Metoprolol Succinate Extended Release 50 mg, formulated for the effective management of hypertension and long-term cardiovascular protection. This combination provides dual blood pressure control by combining the advanced dual calcium channel blocking action of Cilnidipine with the sustained beta-1 selective blocking action of Metoprolol Succinate, resulting in superior antihypertensive efficacy, heart rate control, and enhanced cardiovascular and renal protection. Cilnidipine is a unique dual L-type and N-type calcium channel blocker that reduces peripheral vascular resistance, suppresses sympathetic overactivity, improves renal hemodynamics, and minimizes reflex tachycardia. Metoprolol Succinate Extended Release is a long-acting beta-1 selective blocker that reduces heart rate, myocardial contractility, and cardiac workload while providing sustained 24-hour cardiovascular control. CILROOT-50 is particularly beneficial in patients with hypertension associated with tachycardia, diabetes, chronic kidney disease, coronary artery disease, metabolic syndrome, obesity, and patients requiring combination antihypertensive therapy with heart rate control. Technical Knowledge of Cilnidipine and Metoprolol Succinate Extended Release Cilnidipine blocks both L-type calcium channels in vascular smooth muscle and N-type calcium channels in sympathetic nerve terminals. This dual mechanism reduces arterial vasoconstriction while decreasing sympathetic neurotransmitter release, resulting in sustained blood pressure reduction, improved renal perfusion, reduced glomerular hypertension, and better autonomic control. Metoprolol Succinate Extended Release selectively blocks beta-1 adrenergic receptors in the heart, reducing sympathetic stimulation, heart rate, myocardial contractility, cardiac output, and renin secretion. The extended-release formulation provides stable plasma concentrations and sustained therapeutic activity throughout the day. The combination of Cilnidipine and Metoprolol Succinate Extended Release provides complementary antihypertensive mechanisms with additional cardiovascular, renal, and endothelial protective benefits. Mechanism of Action Cilnidipine blocks L-type and N-type calcium channels, relaxes vascular smooth muscle, suppresses sympathetic activity, improves renal blood flow, reduces glomerular pressure, and provides sustained antihypertensive action. Metoprolol Succinate Extended Release reduces heart rate, decreases myocardial contractility, lowers cardiac output, suppresses renin release, and reduces myocardial oxygen demand through sustained beta-1 receptor blockade. Key Benefits Effective reduction of systolic and diastolic blood pressure Dual antihypertensive mechanism Provides sustained 24-hour blood pressure control Reduces heart rate and myocardial workload Supports cardiovascular and renal protection Improves endothelial function Reduces sympathetic overactivity Minimizes reflex tachycardia Suitable for long-term hypertension management under medical supervision Clinical Applications CILROOT-50 is commonly prescribed for essential hypertension, hypertension with tachycardia, hypertension with diabetes mellitus, hypertension with chronic kidney disease, hypertension with coronary artery disease, metabolic syndrome, obesity-associated hypertension, and long-term cardiovascular risk reduction. Facts About Cilnidipine and Metoprolol Succinate Extended Release Cilnidipine is an advanced calcium channel blocker with dual L-type and N-type channel blocking properties, providing effective blood pressure control with favorable renal and sympathetic modulation effects. Metoprolol Succinate Extended Release is a long-acting beta-blocker with proven benefits in hypertension, ischemic heart disease, and heart failure. The combination is particularly useful in hypertensive patients requiring both blood pressure reduction and heart rate control. Key Facts Dual calcium channel blocker and beta-blocker combination therapy Cilnidipine 10 mg for vascular and renal protection Metoprolol Succinate Extended Release 50 mg for sustained heart rate control Provides sustained 24-hour antihypertensive action Effective in hypertension with tachycardia and diabetes Evidence-based cardiovascular combination therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity CILROOT-50 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, coronary artery disease, chronic kidney disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination. Why Choose CILROOT-50 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Cilnidipine 10 mg and Metoprolol Succinate Extended Release 50 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented extended-release formulation Controlled-release tablet manufacturing technology Blister and Alu-Alu packaging options CILROOT-50 from DIABGLYM combines effective blood pressure control, sustained heart rate management, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Cilnidipine and Metoprolol Succinate Extended Release formulation.

METROOT-AT Metoprolol Succinate Extended Release 50 mg and Amlodipine 5 mg Tablets Division: DIABGLYM Composition Each extended-release tablet contains: Metoprolol Succinate Extended Release IP equivalent to Metoprolol — 50 mg Amlodipine IP — 5 mg Excipients — q.s. Colour: Approved colour used Dosage form: Extended-release oral tablet Product Description METROOT-AT is a scientifically balanced antihypertensive and cardioprotective combination of Metoprolol Succinate Extended Release 50 mg and Amlodipine 5 mg, formulated for the effective management of hypertension, chronic stable angina, coronary artery disease, and long-term cardiovascular protection. This combination provides dual blood pressure control by combining the sustained beta-1 selective blocking action of Metoprolol Succinate with the long-acting vasodilatory action of Amlodipine, resulting in superior antihypertensive efficacy and enhanced cardiovascular protection. Metoprolol Succinate Extended Release is a long-acting beta-1 selective blocker that reduces heart rate, myocardial contractility, and cardiac workload while providing sustained 24-hour cardiovascular control. Amlodipine is a long-acting calcium channel blocker that relaxes vascular smooth muscle, improves arterial compliance, reduces peripheral vascular resistance, and provides sustained blood pressure control throughout the dosing interval. METROOT-AT is particularly beneficial in patients with hypertension associated with tachycardia, coronary artery disease, chronic stable angina, diabetes, metabolic syndrome, elderly hypertension, and patients requiring combination antihypertensive therapy with heart rate control. Technical Knowledge of Metoprolol Succinate Extended Release and Amlodipine Metoprolol Succinate Extended Release selectively blocks beta-1 adrenergic receptors in the heart, reducing sympathetic stimulation, heart rate, myocardial contractility, cardiac output, and renin secretion. The extended-release formulation provides stable plasma concentrations and sustained therapeutic activity throughout the day. Amlodipine inhibits L-type calcium channels in vascular smooth muscle, producing sustained arterial vasodilation, reducing peripheral vascular resistance, improving vascular compliance, and maintaining stable blood pressure control throughout the dosing interval. The combination of Metoprolol Succinate Extended Release and Amlodipine provides complementary antihypertensive mechanisms with additional anti-anginal and cardiovascular protective benefits. Mechanism of Action Metoprolol Succinate Extended Release reduces heart rate, decreases myocardial contractility, lowers cardiac output, suppresses renin release, and reduces myocardial oxygen demand through sustained beta-1 receptor blockade. Amlodipine blocks L-type calcium channels, relaxes vascular smooth muscle, reduces arterial resistance, improves vascular compliance, enhances coronary blood flow, and provides sustained antihypertensive and anti-anginal action. Key Benefits Effective reduction of systolic and diastolic blood pressure Dual antihypertensive mechanism Provides sustained 24-hour blood pressure control Reduces heart rate and myocardial workload Supports cardiovascular protection Improves vascular compliance Reduces peripheral vascular resistance Provides anti-anginal benefits Suitable for long-term hypertension and cardiovascular management under medical supervision Clinical Applications METROOT-AT is commonly prescribed for essential hypertension, hypertension with tachycardia, hypertension with coronary artery disease, chronic stable angina, hypertension with diabetes mellitus, metabolic syndrome, elderly hypertension, and long-term cardiovascular risk reduction. Facts About Metoprolol Succinate Extended Release and Amlodipine Metoprolol Succinate Extended Release is a long-acting beta-blocker with proven benefits in hypertension, ischemic heart disease, and heart failure. Amlodipine is one of the most extensively prescribed calcium channel blockers worldwide and provides effective long-term blood pressure control and anti-anginal efficacy. The combination is widely recommended for patients requiring both blood pressure reduction and heart rate control with additional coronary protection. Key Facts Beta-blocker and calcium channel blocker combination therapy Metoprolol Succinate Extended Release 50 mg for sustained heart rate control Amlodipine 5 mg for sustained arterial vasodilation Provides 24-hour antihypertensive and anti-anginal action Effective in hypertension with coronary artery disease Evidence-based cardiovascular combination therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity METROOT-AT is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, coronary artery disease, diabetes, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination. Why Choose METROOT-AT for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Metoprolol Succinate Extended Release 50 mg and Amlodipine 5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented extended-release formulation Controlled-release tablet manufacturing technology Blister and Alu-Alu packaging options METROOT-AT from DIABGLYM combines effective blood pressure control, sustained heart rate management, comprehensive cardiovascular protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Metoprolol Succinate Extended Release and Amlodipine formulation.

ATENOROOT 25 Atenolol 25 mg Tablets Division: DIABGLYM Composition Each tablet contains: Atenolol IP — 25 mg Excipients — q.s. Colour: Approved colour used Dosage form: Oral tablet Product Description ATENOROOT 25 contains Atenolol 25 mg, a cardioselective beta-1 adrenergic receptor blocker formulated for the effective management of hypertension, angina pectoris, cardiac arrhythmias, and long-term cardiovascular protection. Atenolol provides sustained blood pressure control by reducing heart rate, myocardial contractility, cardiac output, and myocardial oxygen demand, making it an important therapeutic option in cardiovascular disease management. Atenolol is widely prescribed in cardiology and internal medicine for patients with essential hypertension, chronic stable angina, supraventricular tachyarrhythmias, ischemic heart disease, post-myocardial infarction care, and cardiovascular risk reduction. It helps reduce systolic and diastolic blood pressure, control heart rate, decrease cardiac workload, and lower the risk of recurrent cardiovascular events. ATENOROOT 25 is particularly beneficial for patients initiating beta-blocker therapy, elderly patients, individuals requiring lower-dose antihypertensive treatment, hypertension associated with tachycardia, coronary artery disease, and long-term cardiovascular protection. Technical Knowledge of Atenolol Atenolol selectively blocks beta-1 adrenergic receptors in the heart, reducing sympathetic stimulation, heart rate, myocardial contractility, cardiac output, and renin secretion. This results in reduced myocardial oxygen demand, prolonged diastolic filling time, improved coronary perfusion, and effective control of blood pressure and heart rate. Because of its cardioselective action, Atenolol primarily affects cardiac beta-1 receptors with less effect on beta-2 receptors compared with non-selective beta-blockers, making it suitable for many patients requiring long-term cardiovascular therapy. Mechanism of Action Atenolol selectively blocks beta-1 adrenergic receptors, reduces heart rate and myocardial contractility, decreases cardiac output, suppresses renin release, lowers myocardial oxygen demand, improves coronary perfusion, and provides sustained cardiovascular protection. Key Benefits Effective reduction of systolic and diastolic blood pressure Reduces heart rate and myocardial workload Provides sustained antihypertensive action Supports long-term cardiovascular protection Helps prevent chronic angina attacks Controls supraventricular arrhythmias Reduces the risk of recurrent cardiovascular events Suitable for low-dose cardiovascular therapy Convenient once-daily dosing Suitable for long-term cardiovascular management under medical supervision Clinical Applications ATENOROOT 25 is commonly prescribed for essential hypertension, chronic stable angina, supraventricular tachyarrhythmias, ischemic heart disease, post-myocardial infarction management, hypertension with tachycardia, elderly hypertension, and long-term cardiovascular risk reduction. Facts About Atenolol Atenolol is a well-established cardioselective beta-blocker with extensive clinical experience in hypertension, angina, and cardiovascular disease management. It has demonstrated significant benefits in heart rate control, reduction of myocardial oxygen demand, blood pressure management, and prevention of recurrent cardiovascular events in appropriately selected patients. The 25 mg strength is particularly useful for therapy initiation, elderly patients, and patients requiring individualized dose titration. Key Facts Cardioselective beta-1 adrenergic blocker Atenolol 25 mg for blood pressure and heart rate control Reduces myocardial oxygen demand Effective in hypertension, angina, and arrhythmias Supports long-term cardiovascular protection Evidence-based beta-blocker therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity ATENOROOT 25 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, coronary artery disease, diabetes, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this formulation. Why Choose ATENOROOT 25 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Atenolol 25 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented formulation Moisture-controlled tablet manufacturing Blister and Alu-Alu packaging options ATENOROOT 25 from DIABGLYM combines effective blood pressure control, heart rate management, comprehensive cardiovascular protection, evidence-based beta-blocker therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Atenolol formulation.

ATENOROOT 50 Atenolol 50 mg Tablets Division: DIABGLYM Composition Each tablet contains: Atenolol IP — 50 mg Excipients — q.s. Colour: Approved colour used Dosage form: Oral tablet Product Description ATENOROOT 50 contains Atenolol 50 mg, a cardioselective beta-1 adrenergic receptor blocker formulated for the effective management of hypertension, angina pectoris, cardiac arrhythmias, and long-term cardiovascular protection. Atenolol provides sustained blood pressure control by reducing heart rate, myocardial contractility, cardiac output, and myocardial oxygen demand, making it an important therapeutic option in cardiovascular disease management. Atenolol is widely prescribed in cardiology and internal medicine for patients with essential hypertension, chronic stable angina, supraventricular tachyarrhythmias, ischemic heart disease, post-myocardial infarction care, and cardiovascular risk reduction. It helps reduce systolic and diastolic blood pressure, control heart rate, decrease cardiac workload, and lower the risk of recurrent cardiovascular events. ATENOROOT 50 is particularly beneficial for patients with hypertension associated with tachycardia, coronary artery disease, chronic stable angina, ischemic heart disease, arrhythmias, and patients requiring long-term beta-blocker therapy. Technical Knowledge of Atenolol Atenolol selectively blocks beta-1 adrenergic receptors in the heart, reducing sympathetic stimulation, heart rate, myocardial contractility, cardiac output, and renin secretion. This results in reduced myocardial oxygen demand, prolonged diastolic filling time, improved coronary perfusion, and effective control of blood pressure and heart rate. Because of its cardioselective action, Atenolol primarily affects cardiac beta-1 receptors with less effect on beta-2 receptors compared with non-selective beta-blockers, making it suitable for many patients requiring long-term cardiovascular therapy. Mechanism of Action Atenolol selectively blocks beta-1 adrenergic receptors, reduces heart rate and myocardial contractility, decreases cardiac output, suppresses renin release, lowers myocardial oxygen demand, improves coronary perfusion, and provides sustained cardiovascular protection. Key Benefits Effective reduction of systolic and diastolic blood pressure Reduces heart rate and myocardial workload Provides sustained antihypertensive action Supports long-term cardiovascular protection Helps prevent chronic angina attacks Controls supraventricular arrhythmias Reduces the risk of recurrent cardiovascular events Suitable for long-term cardiovascular management under medical supervision Clinical Applications ATENOROOT 50 is commonly prescribed for essential hypertension, chronic stable angina, supraventricular tachyarrhythmias, ischemic heart disease, post-myocardial infarction management, hypertension with tachycardia, and long-term cardiovascular risk reduction. Facts About Atenolol Atenolol is a well-established cardioselective beta-blocker with extensive clinical experience in hypertension, angina, and cardiovascular disease management. It has demonstrated significant benefits in heart rate control, reduction of myocardial oxygen demand, blood pressure management, and prevention of recurrent cardiovascular events in appropriately selected patients. Key Facts Cardioselective beta-1 adrenergic blocker Atenolol 50 mg for blood pressure and heart rate control Reduces myocardial oxygen demand Effective in hypertension, angina, and arrhythmias Supports long-term cardiovascular protection Evidence-based beta-blocker therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity ATENOROOT 50 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, coronary artery disease, diabetes, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this formulation. Why Choose ATENOROOT 50 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Atenolol 50 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented formulation Moisture-controlled tablet manufacturing Blister and Alu-Alu packaging options ATENOROOT 50 from DIABGLYM combines effective blood pressure control, heart rate management, comprehensive cardiovascular protection, evidence-based beta-blocker therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Atenolol formulation.

LOSAROOT AT Losartan Potassium 25 mg and Atenolol 25 mg Tablets Division: DIABGLYM Composition Each tablet contains: Losartan Potassium IP — 25 mg Atenolol IP — 25 mg Excipients — q.s. Colour: Approved colour used Dosage form: Oral tablet Product Description LOSAROOT AT is a scientifically balanced antihypertensive combination of Losartan Potassium 25 mg and Atenolol 25 mg, formulated for the effective management of hypertension and long-term cardiovascular protection. This combination provides dual blood pressure control by combining the renin-angiotensin system blockade of Losartan with the beta-1 selective blocking action of Atenolol, resulting in effective antihypertensive efficacy, heart rate control, and enhanced cardiovascular protection. Losartan Potassium is an angiotensin II receptor blocker (ARB) that promotes vasodilation, reduces peripheral vascular resistance, decreases aldosterone secretion, and provides cardiovascular and renal protection. Atenolol is a cardioselective beta-1 blocker that reduces heart rate, myocardial contractility, cardiac output, and myocardial oxygen demand, making it particularly useful in hypertensive patients with tachycardia or coronary artery disease. LOSAROOT AT is particularly beneficial in patients with hypertension associated with tachycardia, coronary artery disease, ischemic heart disease, diabetes, chronic kidney disease, and patients requiring combination antihypertensive therapy with heart rate control. Technical Knowledge of Losartan Potassium and Atenolol Losartan selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction, aldosterone secretion, sympathetic activation, and vascular remodeling. It improves vascular function and provides significant renal protection, particularly in diabetic patients. Atenolol selectively blocks beta-1 adrenergic receptors in the heart, reducing sympathetic stimulation, heart rate, myocardial contractility, cardiac output, and renin secretion. This decreases myocardial oxygen demand and provides effective cardiovascular control. The combination of Losartan and Atenolol provides complementary antihypertensive mechanisms with additional cardiovascular and renal protective benefits. Mechanism of Action Losartan blocks AT1 receptors, promotes vasodilation, reduces peripheral vascular resistance, decreases aldosterone secretion, improves vascular function, and protects cardiovascular and renal tissues. Atenolol selectively blocks beta-1 receptors, reduces heart rate and myocardial contractility, lowers cardiac output, suppresses renin release, and reduces myocardial oxygen demand. Key Benefits Effective reduction of systolic and diastolic blood pressure Dual antihypertensive mechanism Provides sustained blood pressure control Reduces heart rate and myocardial workload Supports cardiovascular and renal protection Improves vascular function Effective in hypertension with tachycardia Suitable for long-term hypertension management under medical supervision Clinical Applications LOSAROOT AT is commonly prescribed for essential hypertension, hypertension with tachycardia, hypertension with coronary artery disease, hypertension with ischemic heart disease, hypertension with diabetes mellitus, hypertension with chronic kidney disease, and long-term cardiovascular risk reduction. Facts About Losartan Potassium and Atenolol Losartan is a well-established ARB with proven cardiovascular and renal protective benefits. Atenolol is a cardioselective beta-blocker with extensive clinical experience in hypertension, angina, and cardiovascular disease management. The combination is widely used in patients requiring both blood pressure reduction and heart rate control with additional cardiovascular protection. Key Facts ARB and beta-blocker combination therapy Losartan Potassium 25 mg for vascular and renal protection Atenolol 25 mg for heart rate control Provides sustained antihypertensive action Effective in hypertension with coronary artery disease and tachycardia Evidence-based cardiovascular combination therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity LOSAROOT AT is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, coronary artery disease, chronic kidney disease, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination. Why Choose LOSAROOT AT for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Losartan Potassium 25 mg and Atenolol 25 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented formulation Moisture-controlled tablet manufacturing Blister and Alu-Alu packaging options LOSAROOT AT from DIABGLYM combines effective blood pressure control, heart rate management, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Losartan Potassium and Atenolol formulation.

MESROOT-1.2 Mesalamine Delayed Release 1200 mg Tablets Division: CHEMSROOT Composition Each delayed-release tablet contains: Mesalamine IP — 1200 mg Excipients — q.s. Colour: Approved colour used Dosage form: Delayed-release oral tablet Product Description MESROOT-1.2 contains Mesalamine Delayed Release 1200 mg, a high-strength anti-inflammatory aminosalicylate formulation designed for the treatment and maintenance of remission in ulcerative colitis and other inflammatory bowel diseases (IBD). The delayed-release formulation ensures targeted drug delivery to the colon, where Mesalamine exerts its local anti-inflammatory action on the intestinal mucosa. Mesalamine is widely prescribed by gastroenterologists for patients with mild to moderate ulcerative colitis, extensive ulcerative colitis, pancolitis, and long-term maintenance therapy to reduce disease relapse. It helps decrease intestinal inflammation, promote mucosal healing, reduce rectal bleeding and diarrhea, and maintain long-term remission in patients with inflammatory bowel disease. MESROOT-1.2 is particularly beneficial for patients requiring high-dose Mesalamine therapy, extensive colonic involvement, targeted colonic drug delivery, maintenance of remission, and effective anti-inflammatory treatment with minimal systemic absorption. Technical Knowledge of Mesalamine Delayed Release Mesalamine (5-aminosalicylic acid) acts locally within the intestinal mucosa by inhibiting cyclooxygenase and lipoxygenase pathways, reducing the synthesis of inflammatory prostaglandins and leukotrienes. It also modulates cytokine production, inhibits nuclear factor-kappa B (NF-kB) activation, reduces oxidative stress, and suppresses inflammatory cell migration within the colon. The delayed-release tablet is formulated with pH-dependent coating technology that protects the drug from release in the stomach and proximal small intestine, allowing targeted release in the terminal ileum and colon, where inflammation is most prominent in ulcerative colitis. Mechanism of Action Mesalamine inhibits cyclooxygenase and lipoxygenase pathways, reduces prostaglandin and leukotriene synthesis, suppresses inflammatory cytokines, decreases oxidative stress, promotes mucosal healing, and reduces intestinal inflammation through local colonic action. Key Benefits Targets inflammation directly in the colon Promotes mucosal healing Helps induce and maintain remission in ulcerative colitis Reduces rectal bleeding and diarrhea Provides targeted delayed-release colonic delivery Minimizes systemic drug exposure Supports long-term inflammatory bowel disease management Suitable for high-dose therapy under medical supervision Clinical Applications MESROOT-1.2 is commonly prescribed for mild to moderate ulcerative colitis, extensive ulcerative colitis, pancolitis, maintenance of ulcerative colitis remission, inflammatory bowel disease, long-term colonic anti-inflammatory therapy, and patients requiring high-dose Mesalamine treatment. Facts About Mesalamine Mesalamine is considered first-line therapy for mild to moderate ulcerative colitis and maintenance of remission. Delayed-release formulations are specifically designed to deliver the drug to the colon, improving therapeutic efficacy while minimizing systemic adverse effects. The 1200 mg delayed-release strength provides higher therapeutic dosing convenience, improved patient adherence, effective mucosal healing, and sustained remission maintenance in patients with extensive ulcerative colitis. Key Facts High-strength delayed-release aminosalicylate therapy Mesalamine 1200 mg for targeted colonic anti-inflammatory treatment Promotes mucosal healing and remission maintenance Effective in extensive ulcerative colitis and inflammatory bowel disease Minimizes systemic drug exposure Evidence-based gastroenterology therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity MESROOT-1.2 is an excellent product for PCD Pharma Franchise, Gastroenterology Franchise, and Specialty Pharma Franchise across India. The increasing prevalence of ulcerative colitis, inflammatory bowel disease, gastrointestinal inflammatory disorders, and long-term maintenance therapy creates strong prescription demand and excellent market potential for this formulation. Why Choose MESROOT-1.2 for PCD Pharma Franchise? High prescription potential Strong gastroenterologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and specialty marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Mesalamine Delayed Release 1200 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and specialty gastroenterology businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented delayed-release formulation Advanced pH-dependent coating technology Blister and Alu-Alu packaging options MESROOT-1.2 from CHEMSROOT combines targeted colonic anti-inflammatory therapy, high-strength mucosal healing support, evidence-based ulcerative colitis management, and high-quality pharmaceutical manufacturing, making it an ideal product for gastroenterologists, physicians, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Mesalamine delayed-release formulation.

METROOT-AT Metoprolol Succinate Extended Release 23.75 mg and Amlodipine 5 mg Tablets Division: DIABGLYM Composition Each extended-release tablet contains: Metoprolol Succinate Extended Release IP equivalent to Metoprolol — 23.75 mg Amlodipine IP — 5 mg Excipients — q.s. Colour: Approved colour used Dosage form: Extended-release oral tablet Product Description METROOT-AT is a scientifically balanced antihypertensive and cardioprotective combination of Metoprolol Succinate Extended Release 23.75 mg and Amlodipine 5 mg, formulated for the effective management of hypertension, chronic stable angina, coronary artery disease, and long-term cardiovascular protection. This combination provides dual blood pressure control by combining the sustained beta-1 selective blocking action of Metoprolol Succinate with the long-acting vasodilatory action of Amlodipine, resulting in superior antihypertensive efficacy and enhanced cardiovascular protection. Metoprolol Succinate Extended Release is a long-acting beta-1 selective blocker that reduces heart rate, myocardial contractility, and cardiac workload while providing sustained 24-hour cardiovascular control. Amlodipine is a long-acting calcium channel blocker that relaxes vascular smooth muscle, improves arterial compliance, reduces peripheral vascular resistance, and provides sustained blood pressure control throughout the dosing interval. METROOT-AT is particularly beneficial in patients with hypertension associated with tachycardia, coronary artery disease, chronic stable angina, diabetes, metabolic syndrome, elderly hypertension, and patients requiring combination antihypertensive therapy with heart rate control. Technical Knowledge of Metoprolol Succinate Extended Release and Amlodipine Metoprolol Succinate Extended Release selectively blocks beta-1 adrenergic receptors in the heart, reducing sympathetic stimulation, heart rate, myocardial contractility, cardiac output, and renin secretion. The extended-release formulation provides stable plasma concentrations and sustained therapeutic activity throughout the day. Amlodipine inhibits L-type calcium channels in vascular smooth muscle, producing sustained arterial vasodilation, reducing peripheral vascular resistance, improving vascular compliance, and maintaining stable blood pressure control throughout the dosing interval. The combination of Metoprolol Succinate Extended Release and Amlodipine provides complementary antihypertensive mechanisms with additional anti-anginal and cardiovascular protective benefits. Mechanism of Action Metoprolol Succinate Extended Release reduces heart rate, decreases myocardial contractility, lowers cardiac output, suppresses renin release, and reduces myocardial oxygen demand through sustained beta-1 receptor blockade. Amlodipine blocks L-type calcium channels, relaxes vascular smooth muscle, reduces arterial resistance, improves vascular compliance, enhances coronary blood flow, and provides sustained antihypertensive and anti-anginal action. Key Benefits Effective reduction of systolic and diastolic blood pressure Dual antihypertensive mechanism Provides sustained 24-hour blood pressure control Reduces heart rate and myocardial workload Supports cardiovascular protection Improves vascular compliance Reduces peripheral vascular resistance Provides anti-anginal benefits Suitable for long-term hypertension and cardiovascular management under medical supervision Clinical Applications METROOT-AT is commonly prescribed for essential hypertension, hypertension with tachycardia, hypertension with coronary artery disease, chronic stable angina, hypertension with diabetes mellitus, metabolic syndrome, elderly hypertension, and long-term cardiovascular risk reduction. Facts About Metoprolol Succinate Extended Release and Amlodipine Metoprolol Succinate Extended Release is a long-acting beta-blocker with proven benefits in hypertension, ischemic heart disease, and heart failure. Amlodipine is one of the most extensively prescribed calcium channel blockers worldwide and provides effective long-term blood pressure control and anti-anginal efficacy. The combination is widely recommended for patients requiring both blood pressure reduction and heart rate control with additional coronary protection. Key Facts Beta-blocker and calcium channel blocker combination therapy Metoprolol Succinate Extended Release 23.75 mg for sustained heart rate control Amlodipine 5 mg for sustained arterial vasodilation Provides 24-hour antihypertensive and anti-anginal action Effective in hypertension with coronary artery disease Evidence-based cardiovascular combination therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity METROOT-AT is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, coronary artery disease, diabetes, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination. Why Choose METROOT-AT for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Metoprolol Succinate Extended Release 23.75 mg and Amlodipine 5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented extended-release formulation Controlled-release tablet manufacturing technology Blister and Alu-Alu packaging options METROOT-AT from DIABGLYM combines effective blood pressure control, sustained heart rate management, comprehensive cardiovascular protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Metoprolol Succinate Extended Release and Amlodipine formulation.

METROOT-AT Metoprolol Succinate Extended Release 50 mg and Amlodipine 5 mg Tablets Division: DIABGLYM Composition Each extended-release tablet contains: Metoprolol Succinate Extended Release IP equivalent to Metoprolol — 50 mg Amlodipine IP — 5 mg Excipients — q.s. Colour: Approved colour used Dosage form: Extended-release oral tablet Product Description METROOT-AT is a scientifically balanced antihypertensive and cardioprotective combination of Metoprolol Succinate Extended Release 50 mg and Amlodipine 5 mg, formulated for the effective management of hypertension, chronic stable angina, coronary artery disease, and long-term cardiovascular protection. This combination provides dual blood pressure control by combining the sustained beta-1 selective blocking action of Metoprolol Succinate with the long-acting vasodilatory action of Amlodipine, resulting in superior antihypertensive efficacy and enhanced cardiovascular protection. Metoprolol Succinate Extended Release is a long-acting beta-1 selective blocker that reduces heart rate, myocardial contractility, and cardiac workload while providing sustained 24-hour cardiovascular control. Amlodipine is a long-acting calcium channel blocker that relaxes vascular smooth muscle, improves arterial compliance, reduces peripheral vascular resistance, and provides sustained blood pressure control throughout the dosing interval. METROOT-AT is particularly beneficial in patients with hypertension associated with tachycardia, coronary artery disease, chronic stable angina, diabetes, metabolic syndrome, elderly hypertension, and patients requiring combination antihypertensive therapy with heart rate control. Technical Knowledge of Metoprolol Succinate Extended Release and Amlodipine Metoprolol Succinate Extended Release selectively blocks beta-1 adrenergic receptors in the heart, reducing sympathetic stimulation, heart rate, myocardial contractility, cardiac output, and renin secretion. The extended-release formulation provides stable plasma concentrations and sustained therapeutic activity throughout the day. Amlodipine inhibits L-type calcium channels in vascular smooth muscle, producing sustained arterial vasodilation, reducing peripheral vascular resistance, improving vascular compliance, and maintaining stable blood pressure control throughout the dosing interval. The combination of Metoprolol Succinate Extended Release and Amlodipine provides complementary antihypertensive mechanisms with additional anti-anginal and cardiovascular protective benefits. Mechanism of Action Metoprolol Succinate Extended Release reduces heart rate, decreases myocardial contractility, lowers cardiac output, suppresses renin release, and reduces myocardial oxygen demand through sustained beta-1 receptor blockade. Amlodipine blocks L-type calcium channels, relaxes vascular smooth muscle, reduces arterial resistance, improves vascular compliance, enhances coronary blood flow, and provides sustained antihypertensive and anti-anginal action. Key Benefits Effective reduction of systolic and diastolic blood pressure Dual antihypertensive mechanism Provides sustained 24-hour blood pressure control Reduces heart rate and myocardial workload Supports cardiovascular protection Improves vascular compliance Reduces peripheral vascular resistance Provides anti-anginal benefits Suitable for long-term hypertension and cardiovascular management under medical supervision Clinical Applications METROOT-AT is commonly prescribed for essential hypertension, hypertension with tachycardia, hypertension with coronary artery disease, chronic stable angina, hypertension with diabetes mellitus, metabolic syndrome, elderly hypertension, and long-term cardiovascular risk reduction. Facts About Metoprolol Succinate Extended Release and Amlodipine Metoprolol Succinate Extended Release is a long-acting beta-blocker with proven benefits in hypertension, ischemic heart disease, and heart failure. Amlodipine is one of the most extensively prescribed calcium channel blockers worldwide and provides effective long-term blood pressure control and anti-anginal efficacy. The combination is widely recommended for patients requiring both blood pressure reduction and heart rate control with additional coronary protection. Key Facts Beta-blocker and calcium channel blocker combination therapy Metoprolol Succinate Extended Release 50 mg for sustained heart rate control Amlodipine 5 mg for sustained arterial vasodilation Provides 24-hour antihypertensive and anti-anginal action Effective in hypertension with coronary artery disease Evidence-based cardiovascular combination therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity METROOT-AT is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, coronary artery disease, diabetes, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination. Why Choose METROOT-AT for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Metoprolol Succinate Extended Release 50 mg and Amlodipine 5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented extended-release formulation Controlled-release tablet manufacturing technology Blister and Alu-Alu packaging options METROOT-AT from DIABGLYM combines effective blood pressure control, sustained heart rate management, comprehensive cardiovascular protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Metoprolol Succinate Extended Release and Amlodipine formulation.

METROOT-CL Metoprolol Succinate Extended Release 25 mg and Cilnidipine 10 mg Tablets Division: DIABGLYM Composition Each extended-release tablet contains: Metoprolol Succinate Extended Release IP equivalent to Metoprolol — 25 mg Cilnidipine IP — 10 mg Excipients — q.s. Colour: Approved colour used Dosage form: Extended-release oral tablet Product Description METROOT-CL is a scientifically balanced antihypertensive combination of Metoprolol Succinate Extended Release 25 mg and Cilnidipine 10 mg, formulated for the effective management of hypertension and long-term cardiovascular protection. This combination provides dual blood pressure control by combining the sustained beta-1 selective blocking action of Metoprolol Succinate with the advanced dual calcium channel blocking action of Cilnidipine, resulting in superior antihypertensive efficacy and enhanced cardiovascular and renal protection. Metoprolol Succinate Extended Release is a long-acting beta-1 selective blocker that reduces heart rate, myocardial contractility, and cardiac workload while providing sustained 24-hour cardiovascular control. Cilnidipine is a unique dual L-type and N-type calcium channel blocker that reduces peripheral vascular resistance, suppresses sympathetic overactivity, improves renal hemodynamics, and minimizes reflex tachycardia. METROOT-CL is particularly beneficial in patients with hypertension associated with tachycardia, diabetes, chronic kidney disease, coronary artery disease, metabolic syndrome, obesity, and patients requiring combination antihypertensive therapy with heart rate control. Technical Knowledge of Metoprolol Succinate Extended Release and Cilnidipine Metoprolol Succinate Extended Release selectively blocks beta-1 adrenergic receptors in the heart, reducing sympathetic stimulation, heart rate, myocardial contractility, cardiac output, and renin secretion. The extended-release formulation provides stable plasma concentrations and sustained therapeutic activity throughout the day. Cilnidipine blocks both L-type calcium channels in vascular smooth muscle and N-type calcium channels in sympathetic nerve terminals. This dual mechanism reduces arterial vasoconstriction while decreasing sympathetic neurotransmitter release, resulting in sustained blood pressure reduction, improved renal perfusion, reduced glomerular hypertension, and better autonomic control. The combination of Metoprolol Succinate Extended Release and Cilnidipine provides complementary antihypertensive mechanisms with additional cardiovascular, renal, and endothelial protective benefits. Mechanism of Action Metoprolol Succinate Extended Release reduces heart rate, decreases myocardial contractility, lowers cardiac output, suppresses renin release, and reduces myocardial oxygen demand through sustained beta-1 receptor blockade. Cilnidipine blocks L-type and N-type calcium channels, relaxes vascular smooth muscle, suppresses sympathetic activity, improves renal blood flow, reduces glomerular pressure, and provides sustained antihypertensive action. Key Benefits Effective reduction of systolic and diastolic blood pressure Dual antihypertensive mechanism Provides sustained 24-hour blood pressure control Reduces heart rate and myocardial workload Supports cardiovascular and renal protection Improves endothelial function Reduces sympathetic overactivity Minimizes reflex tachycardia Suitable for long-term hypertension management under medical supervision Clinical Applications METROOT-CL is commonly prescribed for essential hypertension, hypertension with tachycardia, hypertension with diabetes mellitus, hypertension with chronic kidney disease, hypertension with coronary artery disease, metabolic syndrome, obesity-associated hypertension, and long-term cardiovascular risk reduction. Facts About Metoprolol Succinate Extended Release and Cilnidipine Metoprolol Succinate Extended Release is a long-acting beta-blocker with proven benefits in hypertension, ischemic heart disease, and heart failure. Cilnidipine is an advanced calcium channel blocker with dual L-type and N-type channel blocking properties, providing effective blood pressure control with favorable renal and sympathetic modulation effects. The combination is particularly useful in hypertensive patients requiring both blood pressure reduction and heart rate control. Key Facts Beta-blocker and dual calcium channel blocker combination therapy Metoprolol Succinate Extended Release 25 mg for sustained heart rate control Cilnidipine 10 mg for vascular and renal protection Provides sustained 24-hour antihypertensive action Effective in hypertension with tachycardia and diabetes Evidence-based cardiovascular combination therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity METROOT-CL is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, coronary artery disease, chronic kidney disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination. Why Choose METROOT-CL for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Metoprolol Succinate Extended Release 25 mg and Cilnidipine 10 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented extended-release formulation Controlled-release tablet manufacturing technology Blister and Alu-Alu packaging options METROOT-CL from DIABGLYM combines effective blood pressure control, sustained heart rate management, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Metoprolol Succinate Extended Release and Cilnidipine formulation.

METROOT-XL 12.5 Metoprolol Succinate Extended Release 12.5 mg Tablets Division: DIABGLYM Composition Each extended-release tablet contains: Metoprolol Succinate Extended Release IP equivalent to Metoprolol — 12.5 mg Excipients — q.s. Colour: Approved colour used Dosage form: Extended-release oral tablet Product Description METROOT-XL 12.5 contains Metoprolol Succinate Extended Release 12.5 mg, a long-acting beta-1 selective adrenergic receptor blocker formulated for the effective management of hypertension, angina pectoris, chronic heart failure, post-myocardial infarction care, and long-term cardiovascular protection. The extended-release formulation provides sustained therapeutic activity, ensuring stable blood pressure control, effective heart rate reduction, and continuous cardioprotective benefits. Metoprolol Succinate is widely prescribed in cardiology and internal medicine for patients with essential hypertension, coronary artery disease, chronic heart failure, arrhythmias, ischemic heart disease, and cardiovascular risk reduction. It helps reduce heart rate, myocardial oxygen demand, cardiac workload, and the risk of recurrent cardiovascular events while improving long-term cardiac function. METROOT-XL 12.5 is particularly beneficial for patients initiating beta-blocker therapy, elderly patients, individuals requiring low-dose cardiovascular treatment, chronic heart failure initiation therapy, and patients requiring gradual dose titration with long-term cardiovascular protection. Technical Knowledge of Metoprolol Succinate Extended Release Metoprolol Succinate selectively blocks beta-1 adrenergic receptors in the heart, reducing sympathetic stimulation, heart rate, myocardial contractility, cardiac output, and renin secretion. The extended-release formulation ensures gradual drug release over an extended period, maintaining stable plasma concentrations and minimizing peak-trough fluctuations. This sustained beta-1 blockade reduces myocardial oxygen demand, improves ventricular filling time, decreases arrhythmogenic potential, and provides significant cardiovascular protection in patients with hypertension, coronary artery disease, and heart failure. Mechanism of Action Metoprolol Succinate selectively blocks beta-1 adrenergic receptors, reduces heart rate and myocardial contractility, decreases cardiac output, suppresses renin release, lowers myocardial oxygen demand, improves ventricular function, and provides sustained cardiovascular protection. Key Benefits Effective reduction of systolic and diastolic blood pressure Provides sustained blood pressure and heart rate control Reduces myocardial oxygen demand Supports long-term cardiovascular protection Improves heart failure outcomes Reduces the risk of recurrent cardiovascular events Suitable for low-dose beta-blocker therapy Convenient once-daily extended-release dosing Suitable for long-term cardiovascular management under medical supervision Clinical Applications METROOT-XL 12.5 is commonly prescribed for essential hypertension, chronic stable angina, chronic heart failure, post-myocardial infarction management, left ventricular dysfunction, supraventricular tachycardia, ischemic heart disease, elderly hypertension, and long-term cardiovascular risk reduction. Facts About Metoprolol Succinate Metoprolol Succinate Extended Release is an evidence-based long-acting beta-blocker with proven benefits in hypertension, coronary artery disease, and chronic heart failure. Large clinical trials have demonstrated significant reductions in cardiovascular morbidity, mortality, hospitalization for heart failure, and recurrent myocardial infarction. The 12.5 mg extended-release strength is particularly useful for therapy initiation, heart failure titration, elderly patients, and individualized cardiovascular management. Key Facts Long-acting beta-1 selective blocker Metoprolol Succinate Extended Release 12.5 mg for sustained cardiovascular control Provides blood pressure and heart rate management Effective in hypertension, angina, and chronic heart failure Supports long-term cardiovascular risk reduction Evidence-based beta-blocker therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity METROOT-XL 12.5 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, coronary artery disease, heart failure, diabetes, and cardiovascular disorders creates strong prescription demand and long-term market potential for this formulation. Why Choose METROOT-XL 12.5 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Metoprolol Succinate Extended Release 12.5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented extended-release formulation Controlled-release tablet manufacturing technology Blister and Alu-Alu packaging options METROOT-XL 12.5 from DIABGLYM combines sustained blood pressure control, effective heart rate management, comprehensive cardiovascular protection, evidence-based beta-blocker therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Metoprolol Succinate Extended Release formulation.

METROOT-XL 100 Metoprolol Succinate Extended Release 100 mg Tablets Division: DIABGLYM Composition Each extended-release tablet contains: Metoprolol Succinate Extended Release IP equivalent to Metoprolol — 100 mg Excipients — q.s. Colour: Approved colour used Dosage form: Extended-release oral tablet Product Description METROOT-XL 100 contains Metoprolol Succinate Extended Release 100 mg, a long-acting beta-1 selective adrenergic receptor blocker formulated for the effective management of hypertension, angina pectoris, chronic heart failure, post-myocardial infarction care, and long-term cardiovascular protection. The extended-release formulation provides sustained 24-hour therapeutic activity, ensuring stable blood pressure control, effective heart rate reduction, and continuous cardioprotective benefits. Metoprolol Succinate is widely prescribed in cardiology and internal medicine for patients with essential hypertension, coronary artery disease, chronic heart failure, arrhythmias, ischemic heart disease, and cardiovascular risk reduction. It helps reduce heart rate, myocardial oxygen demand, cardiac workload, and the risk of recurrent cardiovascular events while improving long-term cardiac function. METROOT-XL 100 is particularly beneficial for patients requiring higher-dose beta-blocker therapy, uncontrolled hypertension, chronic heart failure, post-myocardial infarction management, left ventricular dysfunction, and long-term cardiovascular protection. Technical Knowledge of Metoprolol Succinate Extended Release Metoprolol Succinate selectively blocks beta-1 adrenergic receptors in the heart, reducing sympathetic stimulation, heart rate, myocardial contractility, cardiac output, and renin secretion. The extended-release formulation ensures gradual drug release over 24 hours, maintaining stable plasma concentrations and minimizing peak-trough fluctuations. This sustained beta-1 blockade reduces myocardial oxygen demand, improves ventricular filling time, decreases arrhythmogenic potential, and provides significant cardiovascular protection in patients with hypertension, coronary artery disease, and heart failure. Mechanism of Action Metoprolol Succinate selectively blocks beta-1 adrenergic receptors, reduces heart rate and myocardial contractility, decreases cardiac output, suppresses renin release, lowers myocardial oxygen demand, improves ventricular function, and provides sustained cardiovascular protection. Key Benefits Effective reduction of systolic and diastolic blood pressure Provides sustained 24-hour blood pressure and heart rate control Reduces myocardial oxygen demand Supports long-term cardiovascular protection Improves heart failure outcomes Reduces the risk of recurrent cardiovascular events Convenient once-daily extended-release dosing Suitable for long-term cardiovascular management under medical supervision Clinical Applications METROOT-XL 100 is commonly prescribed for essential hypertension, chronic stable angina, chronic heart failure, post-myocardial infarction management, left ventricular dysfunction, supraventricular tachycardia, ischemic heart disease, and long-term cardiovascular risk reduction. Facts About Metoprolol Succinate Metoprolol Succinate Extended Release is an evidence-based long-acting beta-blocker with proven benefits in hypertension, coronary artery disease, and chronic heart failure. Large clinical trials have demonstrated significant reductions in cardiovascular morbidity, mortality, hospitalization for heart failure, and recurrent myocardial infarction. The extended-release formulation provides superior patient compliance and consistent therapeutic efficacy. Key Facts Long-acting beta-1 selective blocker Metoprolol Succinate Extended Release 100 mg for sustained cardiovascular control Provides 24-hour blood pressure and heart rate management Effective in hypertension, angina, and chronic heart failure Supports long-term cardiovascular risk reduction Evidence-based beta-blocker therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity METROOT-XL 100 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, coronary artery disease, heart failure, diabetes, and cardiovascular disorders creates strong prescription demand and long-term market potential for this formulation. Why Choose METROOT-XL 100 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Metoprolol Succinate Extended Release 100 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented extended-release formulation Controlled-release tablet manufacturing technology Blister and Alu-Alu packaging options METROOT-XL 100 from DIABGLYM combines sustained blood pressure control, effective heart rate management, comprehensive cardiovascular protection, evidence-based beta-blocker therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Metoprolol Succinate Extended Release formulation.

MGLROOT-12.5 Chlorthalidone 12.5 mg Tablets Division: DIABGLYM Composition Each tablet contains: Chlorthalidone IP — 12.5 mg Excipients — q.s. Colour: Approved colour used Dosage form: Oral tablet Product Description MGLROOT-12.5 contains Chlorthalidone 12.5 mg, a long-acting thiazide-like diuretic formulated for the effective management of hypertension, edema associated with cardiovascular and renal disorders, and long-term cardiovascular risk reduction. Chlorthalidone provides sustained blood pressure control by promoting sodium and water excretion, reducing plasma volume, decreasing peripheral vascular resistance, and offering prolonged antihypertensive activity. Chlorthalidone is widely prescribed in cardiology, nephrology, and internal medicine for patients with essential hypertension, isolated systolic hypertension, heart failure, chronic kidney disease, and edema-related conditions. It helps reduce systolic and diastolic blood pressure, improve volume control, decrease arterial stiffness, and lower the risk of cardiovascular complications such as stroke, heart failure, and myocardial infarction. MGLROOT-12.5 is particularly beneficial for patients requiring long-duration blood pressure control, elderly hypertensive patients, patients with salt-sensitive hypertension, edema, chronic kidney disease, and long-term diuretic therapy. Technical Knowledge of Chlorthalidone Chlorthalidone acts primarily on the distal convoluted tubule of the nephron by inhibiting sodium and chloride reabsorption. This increases urinary excretion of sodium, chloride, and water, resulting in reduced plasma volume and decreased cardiac output during the initial phase of therapy. Long-term antihypertensive activity is primarily attributed to reduction in peripheral vascular resistance, improvement in vascular compliance, and sustained arterial blood pressure reduction. Chlorthalidone has a longer elimination half-life than hydrochlorothiazide, providing prolonged therapeutic activity and more consistent 24-hour blood pressure control. Mechanism of Action Chlorthalidone inhibits sodium and chloride reabsorption in the distal convoluted tubule, increases urinary sodium and water excretion, reduces plasma volume, decreases peripheral vascular resistance, improves vascular compliance, and lowers blood pressure. Key Benefits Effective reduction of systolic and diastolic blood pressure Provides prolonged 24-hour antihypertensive action Long-acting thiazide-like diuretic therapy Reduces plasma volume and peripheral vascular resistance Supports cardiovascular protection Effective in isolated systolic hypertension Suitable for long-term hypertension management under medical supervision Clinical Applications MGLROOT-12.5 is commonly prescribed for essential hypertension, isolated systolic hypertension, edema associated with heart failure, chronic kidney disease, fluid retention disorders, elderly hypertension, and long-term cardiovascular risk reduction. Facts About Chlorthalidone Chlorthalidone is a long-acting thiazide-like diuretic with extensive clinical evidence supporting its effectiveness in hypertension management and cardiovascular risk reduction. Comparative studies have demonstrated superior duration of antihypertensive action and stronger evidence for cardiovascular event reduction compared with several other diuretics. It is widely recommended in hypertension treatment guidelines because of its proven efficacy in reducing stroke, heart failure, and cardiovascular morbidity. Key Facts Long-acting thiazide-like diuretic Chlorthalidone 12.5 mg for sustained blood pressure control Provides prolonged 24-hour antihypertensive activity Effective in isolated systolic hypertension Supports long-term cardiovascular protection Evidence-based diuretic therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity MGLROOT-12.5 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, Nephrology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, chronic kidney disease, heart failure, and cardiovascular disorders creates strong prescription demand and long-term market potential for this formulation. Why Choose MGLROOT-12.5 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Chlorthalidone 12.5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented formulation Moisture-controlled tablet manufacturing Blister and Alu-Alu packaging options MGLROOT-12.5 from DIABGLYM combines sustained blood pressure control, prolonged diuretic activity, comprehensive cardiovascular protection, evidence-based antihypertensive therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Chlorthalidone formulation.

MIPROOT-1.25 Ramipril 1.25 mg Tablets Division: DIABGLYM Composition Each tablet contains: Ramipril IP — 1.25 mg Excipients — q.s. Colour: Approved colour used Dosage form: Oral tablet Product Description MIPROOT-1.25 contains Ramipril 1.25 mg, a long-acting angiotensin-converting enzyme (ACE) inhibitor formulated for the effective management of hypertension, heart failure, post-myocardial infarction care, diabetic nephropathy, and long-term cardiovascular and renal protection. Ramipril provides sustained blood pressure control by inhibiting the renin-angiotensin-aldosterone system (RAAS), promoting vasodilation, reducing cardiac workload, and protecting vital organs from hypertension-related damage. Ramipril is widely prescribed in cardiology, nephrology, and internal medicine for patients with essential hypertension, diabetes-associated hypertension, chronic kidney disease, heart failure, left ventricular dysfunction, and established cardiovascular disease. It helps reduce systolic and diastolic blood pressure, improve endothelial function, decrease arterial stiffness, reduce proteinuria, and lower the risk of myocardial infarction, stroke, heart failure progression, and cardiovascular mortality. MIPROOT-1.25 is particularly beneficial for patients initiating ACE inhibitor therapy, elderly hypertensive patients, individuals requiring very low-dose antihypertensive treatment, heart failure initiation therapy, renal protection, and long-term cardiovascular risk reduction. Technical Knowledge of Ramipril Ramipril is converted in the liver to its active metabolite Ramiprilat, which inhibits angiotensin-converting enzyme. This reduces the formation of angiotensin II, decreases aldosterone secretion, promotes vasodilation, reduces sodium and water retention, improves endothelial function, and enhances arterial compliance. Ramipril also reduces bradykinin degradation, contributing to improved vascular function and nitric oxide-mediated vasodilation. Its long duration of action provides effective once-daily blood pressure control and sustained cardiovascular and renal protection. Mechanism of Action Ramipril inhibits angiotensin-converting enzyme, reduces angiotensin II formation, decreases aldosterone secretion, promotes vasodilation, improves endothelial function, reduces peripheral vascular resistance, decreases cardiac afterload, and provides cardiovascular and renal protection. Key Benefits Effective reduction of systolic and diastolic blood pressure Provides sustained blood pressure control Supports cardiovascular and renal protection Improves endothelial function Reduces arterial stiffness Decreases cardiac workload Helps reduce proteinuria Suitable for very low-dose antihypertensive therapy Convenient once-daily dosing Suitable for long-term hypertension and cardiovascular management under medical supervision Clinical Applications MIPROOT-1.25 is commonly prescribed for essential hypertension, hypertension with diabetes mellitus, hypertension with chronic kidney disease, diabetic nephropathy, chronic heart failure, post-myocardial infarction management, left ventricular dysfunction, elderly hypertension, and long-term cardiovascular risk reduction. Facts About Ramipril Ramipril is an evidence-based ACE inhibitor with extensive clinical research demonstrating significant reductions in cardiovascular morbidity and mortality. It is widely recommended in international hypertension, heart failure, diabetic nephropathy, and coronary artery disease guidelines because of its proven benefits in blood pressure control, vascular protection, renal preservation, and prevention of major cardiovascular events. The 1.25 mg strength is particularly useful for therapy initiation, elderly patients, heart failure initiation therapy, and patients requiring individualized dose titration. Key Facts Long-acting ACE inhibitor Ramipril 1.25 mg for cardiovascular and renal protection Provides sustained antihypertensive action Effective in hypertension, heart failure, and diabetic nephropathy Supports long-term cardiovascular risk reduction Evidence-based ACE inhibitor therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity MIPROOT-1.25 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, Nephrology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, chronic kidney disease, heart failure, and cardiovascular disorders creates strong prescription demand and long-term market potential for this formulation. Why Choose MIPROOT-1.25 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Ramipril 1.25 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented formulation Moisture-controlled tablet manufacturing Blister and Alu-Alu packaging options MIPROOT-1.25 from DIABGLYM combines effective blood pressure control, comprehensive cardiovascular and renal protection, evidence-based ACE inhibitor therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Ramipril formulation.

MIPROOT-2.5 Ramipril 2.5 mg Tablets Division: DIABGLYM Composition Each tablet contains: Ramipril IP — 2.5 mg Excipients — q.s. Colour: Approved colour used Dosage form: Oral tablet Product Description MIPROOT-2.5 contains Ramipril 2.5 mg, a long-acting angiotensin-converting enzyme (ACE) inhibitor formulated for the effective management of hypertension, heart failure, post-myocardial infarction care, diabetic nephropathy, and long-term cardiovascular and renal protection. Ramipril provides sustained blood pressure control by inhibiting the renin-angiotensin-aldosterone system (RAAS), promoting vasodilation, reducing cardiac workload, and protecting vital organs from hypertension-related damage. Ramipril is widely prescribed in cardiology, nephrology, and internal medicine for patients with essential hypertension, diabetes-associated hypertension, chronic kidney disease, heart failure, left ventricular dysfunction, and established cardiovascular disease. It helps reduce systolic and diastolic blood pressure, improve endothelial function, decrease arterial stiffness, reduce proteinuria, and lower the risk of myocardial infarction, stroke, heart failure progression, and cardiovascular mortality. MIPROOT-2.5 is particularly beneficial for patients initiating ACE inhibitor therapy, elderly hypertensive patients, individuals requiring lower-dose antihypertensive treatment, renal protection, and long-term cardiovascular risk reduction. Technical Knowledge of Ramipril Ramipril is converted in the liver to its active metabolite Ramiprilat, which inhibits angiotensin-converting enzyme. This reduces the formation of angiotensin II, decreases aldosterone secretion, promotes vasodilation, reduces sodium and water retention, improves endothelial function, and enhances arterial compliance. Ramipril also reduces bradykinin degradation, contributing to improved vascular function and nitric oxide-mediated vasodilation. Its long duration of action provides effective once-daily blood pressure control and sustained cardiovascular and renal protection. Mechanism of Action Ramipril inhibits angiotensin-converting enzyme, reduces angiotensin II formation, decreases aldosterone secretion, promotes vasodilation, improves endothelial function, reduces peripheral vascular resistance, decreases cardiac afterload, and provides cardiovascular and renal protection. Key Benefits Effective reduction of systolic and diastolic blood pressure Provides sustained blood pressure control Supports cardiovascular and renal protection Improves endothelial function Reduces arterial stiffness Decreases cardiac workload Helps reduce proteinuria Suitable for low-dose antihypertensive therapy Convenient once-daily dosing Suitable for long-term hypertension and cardiovascular management under medical supervision Clinical Applications MIPROOT-2.5 is commonly prescribed for essential hypertension, hypertension with diabetes mellitus, hypertension with chronic kidney disease, diabetic nephropathy, chronic heart failure, post-myocardial infarction management, left ventricular dysfunction, elderly hypertension, and long-term cardiovascular risk reduction. Facts About Ramipril Ramipril is an evidence-based ACE inhibitor with extensive clinical research demonstrating significant reductions in cardiovascular morbidity and mortality. It is widely recommended in international hypertension, heart failure, diabetic nephropathy, and coronary artery disease guidelines because of its proven benefits in blood pressure control, vascular protection, renal preservation, and prevention of major cardiovascular events. The 2.5 mg strength is particularly useful for therapy initiation, elderly patients, and patients requiring individualized dose titration. Key Facts Long-acting ACE inhibitor Ramipril 2.5 mg for cardiovascular and renal protection Provides sustained antihypertensive action Effective in hypertension, heart failure, and diabetic nephropathy Supports long-term cardiovascular risk reduction Evidence-based ACE inhibitor therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity MIPROOT-2.5 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, Nephrology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, chronic kidney disease, heart failure, and cardiovascular disorders creates strong prescription demand and long-term market potential for this formulation. Why Choose MIPROOT-2.5 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Ramipril 2.5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented formulation Moisture-controlled tablet manufacturing Blister and Alu-Alu packaging options MIPROOT-2.5 from DIABGLYM combines effective blood pressure control, comprehensive cardiovascular and renal protection, evidence-based ACE inhibitor therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Ramipril formulation.

MIPROOT-5 Ramipril 5 mg Tablets Division: DIABGLYM Composition Each tablet contains: Ramipril IP — 5 mg Excipients — q.s. Colour: Approved colour used Dosage form: Oral tablet Product Description MIPROOT-5 contains Ramipril 5 mg, a long-acting angiotensin-converting enzyme (ACE) inhibitor formulated for the effective management of hypertension, heart failure, post-myocardial infarction care, diabetic nephropathy, and long-term cardiovascular and renal protection. Ramipril provides sustained blood pressure control by inhibiting the renin-angiotensin-aldosterone system (RAAS), promoting vasodilation, reducing cardiac workload, and protecting vital organs from hypertension-related damage. Ramipril is widely prescribed in cardiology, nephrology, and internal medicine for patients with essential hypertension, diabetes-associated hypertension, chronic kidney disease, heart failure, left ventricular dysfunction, and established cardiovascular disease. It helps reduce systolic and diastolic blood pressure, improve endothelial function, decrease arterial stiffness, reduce proteinuria, and lower the risk of myocardial infarction, stroke, heart failure progression, and cardiovascular mortality. MIPROOT-5 is particularly beneficial for patients requiring effective blood pressure control, cardiovascular protection, renal preservation, and long-term ACE inhibitor therapy. Technical Knowledge of Ramipril Ramipril is converted in the liver to its active metabolite Ramiprilat, which inhibits angiotensin-converting enzyme. This reduces the formation of angiotensin II, decreases aldosterone secretion, promotes vasodilation, reduces sodium and water retention, improves endothelial function, and enhances arterial compliance. Ramipril also reduces bradykinin degradation, contributing to improved vascular function and nitric oxide-mediated vasodilation. Its long duration of action provides effective once-daily blood pressure control and sustained cardiovascular and renal protection. Mechanism of Action Ramipril inhibits angiotensin-converting enzyme, reduces angiotensin II formation, decreases aldosterone secretion, promotes vasodilation, improves endothelial function, reduces peripheral vascular resistance, decreases cardiac afterload, and provides cardiovascular and renal protection. Key Benefits Effective reduction of systolic and diastolic blood pressure Provides sustained 24-hour blood pressure control Supports cardiovascular and renal protection Improves endothelial function Reduces arterial stiffness Decreases cardiac workload Helps reduce proteinuria Suitable for long-term hypertension and cardiovascular management under medical supervision Clinical Applications MIPROOT-5 is commonly prescribed for essential hypertension, hypertension with diabetes mellitus, hypertension with chronic kidney disease, diabetic nephropathy, chronic heart failure, post-myocardial infarction management, left ventricular dysfunction, and long-term cardiovascular risk reduction. Facts About Ramipril Ramipril is an evidence-based ACE inhibitor with extensive clinical research demonstrating significant reductions in cardiovascular morbidity and mortality. It is widely recommended in international hypertension, heart failure, diabetic nephropathy, and coronary artery disease guidelines because of its proven benefits in blood pressure control, vascular protection, renal preservation, and prevention of major cardiovascular events. Key Facts Long-acting ACE inhibitor Ramipril 5 mg for cardiovascular and renal protection Provides sustained 24-hour antihypertensive action Effective in hypertension, heart failure, and diabetic nephropathy Supports long-term cardiovascular risk reduction Evidence-based ACE inhibitor therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity MIPROOT-5 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, Nephrology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, chronic kidney disease, heart failure, and cardiovascular disorders creates strong prescription demand and long-term market potential for this formulation. Why Choose MIPROOT-5 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Ramipril 5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented formulation Moisture-controlled tablet manufacturing Blister and Alu-Alu packaging options MIPROOT-5 from DIABGLYM combines effective blood pressure control, comprehensive cardiovascular and renal protection, evidence-based ACE inhibitor therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Ramipril formulation.

MIPROOT-H Ramipril 5 mg and Hydrochlorothiazide 12.5 mg Tablets Division: DIABGLYM Composition Each tablet contains: Ramipril IP — 5 mg Hydrochlorothiazide IP — 12.5 mg Excipients — q.s. Colour: Approved colour used Dosage form: Oral tablet Product Description MIPROOT-H is a scientifically balanced antihypertensive combination of Ramipril 5 mg and Hydrochlorothiazide 12.5 mg, formulated for the effective management of hypertension and long-term cardiovascular and renal protection. This combination provides dual blood pressure control by combining the renin-angiotensin system inhibition of Ramipril with the diuretic action of Hydrochlorothiazide, resulting in superior antihypertensive efficacy and enhanced target organ protection. Ramipril is an angiotensin-converting enzyme (ACE) inhibitor that promotes vasodilation, reduces peripheral vascular resistance, decreases aldosterone secretion, and protects cardiovascular and renal function. Hydrochlorothiazide is a thiazide diuretic that increases sodium and water excretion, reduces plasma volume, decreases peripheral vascular resistance, and enhances the antihypertensive effect of Ramipril. MIPROOT-H is particularly beneficial in patients with uncontrolled hypertension, hypertension associated with diabetes, chronic kidney disease, obesity, metabolic syndrome, elderly hypertension, and patients requiring combination antihypertensive therapy. Technical Knowledge of Ramipril and Hydrochlorothiazide Ramipril is converted to its active metabolite Ramiprilat, which inhibits angiotensin-converting enzyme, reducing angiotensin II formation, decreasing aldosterone secretion, promoting vasodilation, improving endothelial function, and preventing adverse cardiovascular remodeling. Hydrochlorothiazide acts on the distal convoluted tubule of the nephron by inhibiting sodium-chloride reabsorption, resulting in increased urinary excretion of sodium, chloride, and water. Long-term therapy reduces peripheral vascular resistance and contributes to sustained blood pressure reduction. The combination of Ramipril and Hydrochlorothiazide provides complementary antihypertensive mechanisms with additional cardiovascular and renal protective benefits. Mechanism of Action Ramipril inhibits angiotensin-converting enzyme, reduces angiotensin II formation, decreases aldosterone secretion, promotes vasodilation, improves endothelial function, reduces peripheral vascular resistance, and protects cardiovascular and renal tissues. Hydrochlorothiazide promotes sodium and water excretion, reduces plasma volume, decreases peripheral vascular resistance, and enhances antihypertensive efficacy. Key Benefits Effective reduction of systolic and diastolic blood pressure Dual antihypertensive mechanism Provides sustained blood pressure control Supports cardiovascular and renal protection Improves endothelial function Reduces peripheral vascular resistance Effective diuretic support Suitable for long-term hypertension management under medical supervision Clinical Applications MIPROOT-H is commonly prescribed for essential hypertension, uncontrolled hypertension requiring combination therapy, hypertension with diabetes mellitus, hypertension with chronic kidney disease, hypertension with obesity, metabolic syndrome, elderly hypertension, and long-term cardiovascular risk reduction. Facts About Ramipril and Hydrochlorothiazide Ramipril is an evidence-based ACE inhibitor with proven cardiovascular and renal protective benefits. Hydrochlorothiazide is a well-established thiazide diuretic with extensive clinical experience in hypertension management. The combination is widely recommended for patients requiring dual antihypertensive therapy because of its excellent efficacy, tolerability, and target organ protective effects. Key Facts ACE inhibitor and thiazide diuretic combination therapy Ramipril 5 mg for cardiovascular and renal protection Hydrochlorothiazide 12.5 mg for effective diuretic support Provides sustained antihypertensive action Effective in hypertension requiring combination therapy Evidence-based cardiovascular combination therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity MIPROOT-H is an excellent product for PCD Pharma Franchise, Cardiology Franchise, Nephrology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, chronic kidney disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination. Why Choose MIPROOT-H for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Ramipril 5 mg and Hydrochlorothiazide 12.5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented formulation Moisture-controlled tablet manufacturing Blister and Alu-Alu packaging options MIPROOT-H from DIABGLYM combines effective blood pressure control, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Ramipril and Hydrochlorothiazide formulation.

MIPROOT-METO 5/50 Metoprolol Succinate Extended Release 50 mg and Ramipril 5 mg Tablets Division: DIABGLYM Composition Each extended-release tablet contains: Metoprolol Succinate Extended Release IP equivalent to Metoprolol — 50 mg Ramipril IP — 5 mg Excipients — q.s. Colour: Approved colour used Dosage form: Extended-release oral tablet Product Description MIPROOT-METO 5/50 is a scientifically balanced antihypertensive and cardioprotective combination of Metoprolol Succinate Extended Release 50 mg and Ramipril 5 mg, formulated for the effective management of hypertension, coronary artery disease, heart failure, and long-term cardiovascular risk reduction. This combination provides dual cardiovascular protection by combining the sustained beta-1 selective blocking action of Metoprolol Succinate with the renin-angiotensin system inhibition of Ramipril, resulting in effective blood pressure control, reduced cardiac workload, and enhanced cardiovascular and renal protection. Metoprolol Succinate Extended Release is a long-acting beta-1 selective blocker that reduces heart rate, myocardial contractility, and cardiac workload while providing sustained 24-hour cardiovascular control. Ramipril is an angiotensin-converting enzyme (ACE) inhibitor that promotes vasodilation, reduces peripheral vascular resistance, decreases aldosterone secretion, and protects cardiovascular and renal function. MIPROOT-METO 5/50 is particularly beneficial in patients with hypertension associated with coronary artery disease, post-myocardial infarction status, heart failure, diabetes, chronic kidney disease, left ventricular dysfunction, and patients requiring long-term cardioprotective therapy. Technical Knowledge of Metoprolol Succinate Extended Release and Ramipril Metoprolol Succinate Extended Release selectively blocks beta-1 adrenergic receptors in the heart, reducing sympathetic stimulation, heart rate, myocardial contractility, cardiac output, and renin secretion. The extended-release formulation provides stable plasma concentrations and sustained therapeutic activity throughout the day. Ramipril is converted to its active metabolite Ramiprilat, which inhibits angiotensin-converting enzyme, reducing angiotensin II formation, decreasing aldosterone secretion, promoting vasodilation, improving endothelial function, and preventing adverse cardiovascular remodeling. The combination of Metoprolol Succinate Extended Release and Ramipril provides complementary cardiovascular mechanisms with enhanced antihypertensive, cardioprotective, and nephroprotective benefits. Mechanism of Action Metoprolol Succinate Extended Release reduces heart rate, decreases myocardial contractility, lowers cardiac output, suppresses renin release, and reduces myocardial oxygen demand through sustained beta-1 receptor blockade. Ramipril inhibits angiotensin-converting enzyme, reduces angiotensin II formation, decreases aldosterone secretion, promotes vasodilation, improves endothelial function, reduces peripheral vascular resistance, and protects cardiovascular and renal tissues. Key Benefits Effective reduction of systolic and diastolic blood pressure Dual cardioprotective mechanism Provides sustained 24-hour cardiovascular control Reduces heart rate and myocardial workload Supports cardiovascular and renal protection Improves endothelial function Helps prevent adverse cardiac remodeling Suitable for long-term hypertension and cardiovascular management under medical supervision Clinical Applications MIPROOT-METO 5/50 is commonly prescribed for essential hypertension, hypertension with coronary artery disease, hypertension with diabetes mellitus, hypertension with chronic kidney disease, post-myocardial infarction management, chronic heart failure, left ventricular dysfunction, and long-term cardiovascular risk reduction. Facts About Metoprolol Succinate Extended Release and Ramipril Metoprolol Succinate Extended Release is a long-acting beta-blocker with proven benefits in hypertension, ischemic heart disease, and heart failure. Ramipril is an evidence-based ACE inhibitor with extensive clinical research demonstrating significant reductions in cardiovascular morbidity and mortality. The combination provides comprehensive blood pressure control, heart rate reduction, prevention of cardiovascular remodeling, and long-term organ protection. Key Facts Beta-blocker and ACE inhibitor combination therapy Metoprolol Succinate Extended Release 50 mg for sustained heart rate control Ramipril 5 mg for cardiovascular and renal protection Provides 24-hour antihypertensive and cardioprotective action Effective in hypertension, coronary artery disease, and heart failure Evidence-based cardiovascular combination therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity MIPROOT-METO 5/50 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, coronary artery disease, heart failure, and chronic kidney disease creates strong prescription demand and long-term market potential for this combination. Why Choose MIPROOT-METO 5/50 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Metoprolol Succinate Extended Release 50 mg and Ramipril 5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented extended-release formulation Controlled-release tablet manufacturing technology Blister and Alu-Alu packaging options MIPROOT-METO 5/50 from DIABGLYM combines effective blood pressure control, sustained heart rate management, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Metoprolol Succinate Extended Release and Ramipril formulation.

MIPROOT-10 Ramipril 10 mg Tablets Division: DIABGLYM Composition Each tablet contains: Ramipril IP — 10 mg Excipients — q.s. Colour: Approved colour used Dosage form: Oral tablet Product Description MIPROOT-10 contains Ramipril 10 mg, a long-acting angiotensin-converting enzyme (ACE) inhibitor formulated for the effective management of hypertension, heart failure, post-myocardial infarction care, diabetic nephropathy, and long-term cardiovascular and renal protection. Ramipril provides sustained blood pressure control by inhibiting the renin-angiotensin-aldosterone system (RAAS), promoting vasodilation, reducing cardiac workload, and protecting vital organs from hypertension-related damage. Ramipril is widely prescribed in cardiology, nephrology, and internal medicine for patients with essential hypertension, diabetes-associated hypertension, chronic kidney disease, heart failure, left ventricular dysfunction, and established cardiovascular disease. It helps reduce systolic and diastolic blood pressure, improve endothelial function, decrease arterial stiffness, reduce proteinuria, and lower the risk of myocardial infarction, stroke, heart failure progression, and cardiovascular mortality. MIPROOT-10 is particularly beneficial for patients requiring intensive blood pressure control, advanced cardiovascular protection, renal preservation, and long-term ACE inhibitor therapy. Technical Knowledge of Ramipril Ramipril is converted in the liver to its active metabolite Ramiprilat, which inhibits angiotensin-converting enzyme. This reduces the formation of angiotensin II, decreases aldosterone secretion, promotes vasodilation, reduces sodium and water retention, improves endothelial function, and enhances arterial compliance. Ramipril also reduces bradykinin degradation, contributing to improved vascular function and nitric oxide-mediated vasodilation. Its long duration of action provides effective once-daily blood pressure control and sustained cardiovascular and renal protection. Mechanism of Action Ramipril inhibits angiotensin-converting enzyme, reduces angiotensin II formation, decreases aldosterone secretion, promotes vasodilation, improves endothelial function, reduces peripheral vascular resistance, decreases cardiac afterload, and provides cardiovascular and renal protection. Key Benefits Effective reduction of systolic and diastolic blood pressure Provides sustained 24-hour blood pressure control Supports cardiovascular and renal protection Improves endothelial function Reduces arterial stiffness Decreases cardiac workload Helps reduce proteinuria Suitable for long-term hypertension and cardiovascular management under medical supervision Clinical Applications MIPROOT-10 is commonly prescribed for essential hypertension, hypertension with diabetes mellitus, hypertension with chronic kidney disease, diabetic nephropathy, chronic heart failure, post-myocardial infarction management, left ventricular dysfunction, and long-term cardiovascular risk reduction. Facts About Ramipril Ramipril is an evidence-based ACE inhibitor with extensive clinical research demonstrating significant reductions in cardiovascular morbidity and mortality. It is widely recommended in international hypertension, heart failure, diabetic nephropathy, and coronary artery disease guidelines because of its proven benefits in blood pressure control, vascular protection, renal preservation, and prevention of major cardiovascular events. Key Facts Long-acting ACE inhibitor Ramipril 10 mg for intensive cardiovascular and renal protection Provides sustained 24-hour antihypertensive action Effective in hypertension, heart failure, and diabetic nephropathy Supports long-term cardiovascular risk reduction Evidence-based ACE inhibitor therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity MIPROOT-10 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, Nephrology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, chronic kidney disease, heart failure, and cardiovascular disorders creates strong prescription demand and long-term market potential for this formulation. Why Choose MIPROOT-10 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Ramipril 10 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented formulation Moisture-controlled tablet manufacturing Blister and Alu-Alu packaging options MIPROOT-10 from DIABGLYM combines effective blood pressure control, comprehensive cardiovascular and renal protection, evidence-based ACE inhibitor therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Ramipril formulation.

MIPROOT METO 2.5 Metoprolol Succinate Extended Release 50 mg and Ramipril 2.5 mg Tablets Division: DIABGLYM Composition Each extended-release tablet contains: Metoprolol Succinate Extended Release IP equivalent to Metoprolol — 50 mg Ramipril IP — 2.5 mg Excipients — q.s. Colour: Approved colour used Dosage form: Extended-release oral tablet Product Description MIPROOT METO 2.5 is a scientifically balanced antihypertensive and cardioprotective combination of Metoprolol Succinate Extended Release 50 mg and Ramipril 2.5 mg, formulated for the effective management of hypertension, coronary artery disease, heart failure, and long-term cardiovascular risk reduction. This combination provides dual cardiovascular protection by combining the sustained beta-1 selective blocking action of Metoprolol Succinate with the renin-angiotensin system inhibition of Ramipril, resulting in effective blood pressure control, reduced cardiac workload, and enhanced cardiovascular and renal protection. Metoprolol Succinate Extended Release is a long-acting beta-1 selective blocker that reduces heart rate, myocardial contractility, and cardiac workload while providing sustained 24-hour cardiovascular control. Ramipril is an angiotensin-converting enzyme (ACE) inhibitor that promotes vasodilation, reduces peripheral vascular resistance, decreases aldosterone secretion, and protects cardiovascular and renal function. MIPROOT METO 2.5 is particularly beneficial in patients with hypertension associated with coronary artery disease, post-myocardial infarction status, heart failure, diabetes, chronic kidney disease, left ventricular dysfunction, elderly hypertension, and patients requiring lower-dose ACE inhibitor therapy with long-term cardioprotective benefits. Technical Knowledge of Metoprolol Succinate Extended Release and Ramipril Metoprolol Succinate Extended Release selectively blocks beta-1 adrenergic receptors in the heart, reducing sympathetic stimulation, heart rate, myocardial contractility, cardiac output, and renin secretion. The extended-release formulation provides stable plasma concentrations and sustained therapeutic activity throughout the day. Ramipril is converted to its active metabolite Ramiprilat, which inhibits angiotensin-converting enzyme, reducing angiotensin II formation, decreasing aldosterone secretion, promoting vasodilation, improving endothelial function, and preventing adverse cardiovascular remodeling. The combination of Metoprolol Succinate Extended Release and Ramipril provides complementary cardiovascular mechanisms with enhanced antihypertensive, cardioprotective, and nephroprotective benefits. Mechanism of Action Metoprolol Succinate Extended Release reduces heart rate, decreases myocardial contractility, lowers cardiac output, suppresses renin release, and reduces myocardial oxygen demand through sustained beta-1 receptor blockade. Ramipril inhibits angiotensin-converting enzyme, reduces angiotensin II formation, decreases aldosterone secretion, promotes vasodilation, improves endothelial function, reduces peripheral vascular resistance, and protects cardiovascular and renal tissues. Key Benefits Effective reduction of systolic and diastolic blood pressure Dual cardioprotective mechanism Provides sustained 24-hour cardiovascular control Reduces heart rate and myocardial workload Supports cardiovascular and renal protection Improves endothelial function Helps prevent adverse cardiac remodeling Suitable for long-term hypertension and cardiovascular management under medical supervision Clinical Applications MIPROOT METO 2.5 is commonly prescribed for essential hypertension, hypertension with coronary artery disease, hypertension with diabetes mellitus, hypertension with chronic kidney disease, post-myocardial infarction management, chronic heart failure, left ventricular dysfunction, elderly hypertension, and long-term cardiovascular risk reduction. Facts About Metoprolol Succinate Extended Release and Ramipril Metoprolol Succinate Extended Release is a long-acting beta-blocker with proven benefits in hypertension, ischemic heart disease, and heart failure. Ramipril is an evidence-based ACE inhibitor with extensive clinical research demonstrating significant reductions in cardiovascular morbidity and mortality. The combination provides comprehensive blood pressure control, heart rate reduction, prevention of cardiovascular remodeling, and long-term organ protection. The Ramipril 2.5 mg strength is particularly useful for initiation of combination therapy and individualized dose titration. Key Facts Beta-blocker and ACE inhibitor combination therapy Metoprolol Succinate Extended Release 50 mg for sustained heart rate control Ramipril 2.5 mg for cardiovascular and renal protection Provides 24-hour antihypertensive and cardioprotective action Effective in hypertension, coronary artery disease, and heart failure Evidence-based cardiovascular combination therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity MIPROOT METO 2.5 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, coronary artery disease, heart failure, and chronic kidney disease creates strong prescription demand and long-term market potential for this combination. Why Choose MIPROOT METO 2.5 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Metoprolol Succinate Extended Release 50 mg and Ramipril 2.5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented extended-release formulation Controlled-release tablet manufacturing technology Blister and Alu-Alu packaging options MIPROOT METO 2.5 from DIABGLYM combines effective blood pressure control, sustained heart rate management, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Metoprolol Succinate Extended Release and Ramipril formulation.

MIPROOT-METO 5 Metoprolol Succinate Extended Release and Ramipril Tablets Division: DIABGLYM Composition Each extended-release tablet contains: Metoprolol Succinate Extended Release IP equivalent to Metoprolol — 50 mg Ramipril IP — 5 mg Excipients — q.s. Colour: Approved colour used Dosage form: Extended-release oral tablet Product Description MIPROOT-METO 5 is a scientifically balanced antihypertensive and cardioprotective combination of Metoprolol Succinate Extended Release and Ramipril, formulated for the effective management of hypertension, coronary artery disease, heart failure, and long-term cardiovascular risk reduction. This combination provides dual cardiovascular protection by combining the sustained beta-1 selective blocking action of Metoprolol Succinate with the renin-angiotensin system inhibition of Ramipril, resulting in effective blood pressure control, reduced cardiac workload, and enhanced cardiovascular and renal protection. Metoprolol Succinate Extended Release is a long-acting beta-1 selective blocker that reduces heart rate, myocardial contractility, and cardiac workload while providing sustained 24-hour cardiovascular control. Ramipril is an angiotensin-converting enzyme (ACE) inhibitor that promotes vasodilation, reduces peripheral vascular resistance, decreases aldosterone secretion, and protects cardiovascular and renal function. MIPROOT-METO 5 is particularly beneficial in patients with hypertension associated with coronary artery disease, post-myocardial infarction status, heart failure, diabetes, chronic kidney disease, left ventricular dysfunction, and patients requiring long-term cardioprotective therapy. Technical Knowledge of Metoprolol Succinate Extended Release and Ramipril Metoprolol Succinate Extended Release selectively blocks beta-1 adrenergic receptors in the heart, reducing sympathetic stimulation, heart rate, myocardial contractility, cardiac output, and renin secretion. The extended-release formulation provides stable plasma concentrations and sustained therapeutic activity throughout the day. Ramipril is converted to its active metabolite Ramiprilat, which inhibits angiotensin-converting enzyme, reducing angiotensin II formation, decreasing aldosterone secretion, promoting vasodilation, improving endothelial function, and preventing adverse cardiovascular remodeling. The combination of Metoprolol Succinate Extended Release and Ramipril provides complementary cardiovascular mechanisms with enhanced antihypertensive, cardioprotective, and nephroprotective benefits. Mechanism of Action Metoprolol Succinate Extended Release reduces heart rate, decreases myocardial contractility, lowers cardiac output, suppresses renin release, and reduces myocardial oxygen demand through sustained beta-1 receptor blockade. Ramipril inhibits angiotensin-converting enzyme, reduces angiotensin II formation, decreases aldosterone secretion, promotes vasodilation, improves endothelial function, reduces peripheral vascular resistance, and protects cardiovascular and renal tissues. Key Benefits Effective reduction of systolic and diastolic blood pressure Dual cardioprotective mechanism Provides sustained 24-hour cardiovascular control Reduces heart rate and myocardial workload Supports cardiovascular and renal protection Improves endothelial function Helps prevent adverse cardiac remodeling Suitable for long-term hypertension and cardiovascular management under medical supervision Clinical Applications MIPROOT-METO 5 is commonly prescribed for essential hypertension, hypertension with coronary artery disease, hypertension with diabetes mellitus, hypertension with chronic kidney disease, post-myocardial infarction management, chronic heart failure, left ventricular dysfunction, and long-term cardiovascular risk reduction. Facts About Metoprolol Succinate Extended Release and Ramipril Metoprolol Succinate Extended Release is a long-acting beta-blocker with proven benefits in hypertension, ischemic heart disease, and heart failure. Ramipril is an evidence-based ACE inhibitor with extensive clinical research demonstrating significant reductions in cardiovascular morbidity and mortality. The combination provides comprehensive blood pressure control, heart rate reduction, prevention of cardiovascular remodeling, and long-term organ protection. Key Facts Beta-blocker and ACE inhibitor combination therapy Metoprolol Succinate Extended Release for sustained heart rate control Ramipril for cardiovascular and renal protection Provides 24-hour antihypertensive and cardioprotective action Effective in hypertension, coronary artery disease, and heart failure Evidence-based cardiovascular combination therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity MIPROOT-METO 5 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, coronary artery disease, heart failure, and chronic kidney disease creates strong prescription demand and long-term market potential for this combination. Why Choose MIPROOT-METO 5 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Metoprolol Succinate Extended Release and Ramipril Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented extended-release formulation Controlled-release tablet manufacturing technology Blister and Alu-Alu packaging options MIPROOT-METO 5 from DIABGLYM combines effective blood pressure control, sustained heart rate management, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Metoprolol Succinate Extended Release and Ramipril formulation.

MND-0.2 Moxonidine 0.2 mg Tablets Division: DIABGLYM Composition Each tablet contains: Moxonidine IP — 0.2 mg Excipients — q.s. Colour: Approved colour used Dosage form: Oral tablet Product Description MND-0.2 contains Moxonidine 0.2 mg, a centrally acting antihypertensive agent formulated for the effective management of essential hypertension and long-term cardiovascular protection. Moxonidine acts by selectively stimulating imidazoline I1 receptors in the brainstem, reducing sympathetic nervous system activity and lowering peripheral vascular resistance, resulting in effective blood pressure control with improved tolerability compared with many traditional centrally acting antihypertensive agents. Moxonidine is widely prescribed in cardiology and internal medicine for patients with essential hypertension, resistant hypertension, metabolic syndrome, obesity-associated hypertension, diabetes-associated hypertension, and increased sympathetic activity. It helps reduce systolic and diastolic blood pressure, improve insulin sensitivity, decrease sympathetic overactivity, and reduce cardiovascular risk. MND-0.2 is particularly beneficial for patients initiating Moxonidine therapy, elderly hypertensive patients, individuals requiring moderate-dose antihypertensive treatment, metabolic syndrome, obesity, diabetes mellitus, chronic kidney disease, and patients requiring long-term antihypertensive therapy with favorable metabolic effects. Technical Knowledge of Moxonidine Moxonidine selectively stimulates central imidazoline I1 receptors located in the rostral ventrolateral medulla of the brainstem. Activation of these receptors suppresses sympathetic outflow from the central nervous system, resulting in reduced peripheral vascular resistance, decreased heart rate, reduced renin secretion, and sustained blood pressure reduction. Unlike older centrally acting agents, Moxonidine has greater selectivity for imidazoline receptors and less affinity for alpha-2 adrenergic receptors, contributing to a lower incidence of sedation, dry mouth, and other central nervous system adverse effects. Mechanism of Action Moxonidine stimulates central imidazoline I1 receptors, suppresses sympathetic nervous system activity, reduces peripheral vascular resistance, decreases heart rate, lowers blood pressure, reduces renin secretion, and improves autonomic cardiovascular regulation. Key Benefits Effective reduction of systolic and diastolic blood pressure Reduces sympathetic overactivity Provides sustained antihypertensive action May improve insulin sensitivity Supports cardiovascular protection Favorable metabolic profile Suitable for resistant hypertension Convenient once-daily dosing Suitable for long-term hypertension management under medical supervision Clinical Applications MND-0.2 is commonly prescribed for essential hypertension, resistant hypertension, hypertension with metabolic syndrome, hypertension with obesity, hypertension with diabetes mellitus, hypertension with chronic kidney disease, and long-term cardiovascular risk reduction. Facts About Moxonidine Moxonidine is a selective imidazoline receptor agonist with proven efficacy in reducing blood pressure through central sympathetic inhibition. It is particularly valuable in patients with metabolic syndrome, obesity, insulin resistance, and increased sympathetic activity. Clinical studies have demonstrated effective blood pressure reduction with favorable metabolic and autonomic effects. The 0.2 mg strength is commonly used for initiation and maintenance therapy in patients requiring individualized antihypertensive treatment. Key Facts Selective imidazoline I1 receptor agonist Moxonidine 0.2 mg for sympathetic blood pressure control Reduces central sympathetic activity May improve insulin sensitivity Favorable metabolic and cardiovascular profile Evidence-based antihypertensive therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity MND-0.2 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, obesity, metabolic syndrome, and cardiovascular disorders creates strong prescription demand and long-term market potential for this formulation. Why Choose MND-0.2 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Moxonidine 0.2 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented formulation Moisture-controlled tablet manufacturing Blister and Alu-Alu packaging options MND-0.2 from DIABGLYM combines effective blood pressure control, sympathetic modulation, favorable metabolic benefits, evidence-based cardiovascular therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Moxonidine formulation.

MND-0.3 Moxonidine 0.3 mg Tablets Division: DIABGLYM Composition Each tablet contains: Moxonidine IP — 0.3 mg Excipients — q.s. Colour: Approved colour used Dosage form: Oral tablet Product Description MND-0.3 contains Moxonidine 0.3 mg, a centrally acting antihypertensive agent formulated for the effective management of essential hypertension and long-term cardiovascular protection. Moxonidine acts by selectively stimulating imidazoline I1 receptors in the brainstem, reducing sympathetic nervous system activity and lowering peripheral vascular resistance, resulting in effective blood pressure control with improved tolerability compared with many traditional centrally acting antihypertensive agents. Moxonidine is widely prescribed in cardiology and internal medicine for patients with essential hypertension, resistant hypertension, metabolic syndrome, obesity-associated hypertension, diabetes-associated hypertension, and increased sympathetic activity. It helps reduce systolic and diastolic blood pressure, improve insulin sensitivity, decrease sympathetic overactivity, and reduce cardiovascular risk. MND-0.3 is particularly beneficial for patients with uncontrolled hypertension, metabolic syndrome, obesity, diabetes mellitus, chronic kidney disease, and patients requiring long-term antihypertensive therapy with favorable metabolic effects. Technical Knowledge of Moxonidine Moxonidine selectively stimulates central imidazoline I1 receptors located in the rostral ventrolateral medulla of the brainstem. Activation of these receptors suppresses sympathetic outflow from the central nervous system, resulting in reduced peripheral vascular resistance, decreased heart rate, reduced renin secretion, and sustained blood pressure reduction. Unlike older centrally acting agents, Moxonidine has greater selectivity for imidazoline receptors and less affinity for alpha-2 adrenergic receptors, contributing to a lower incidence of sedation, dry mouth, and other central nervous system adverse effects. Mechanism of Action Moxonidine stimulates central imidazoline I1 receptors, suppresses sympathetic nervous system activity, reduces peripheral vascular resistance, decreases heart rate, lowers blood pressure, reduces renin secretion, and improves autonomic cardiovascular regulation. Key Benefits Effective reduction of systolic and diastolic blood pressure Reduces sympathetic overactivity Provides sustained antihypertensive action May improve insulin sensitivity Supports cardiovascular protection Favorable metabolic profile Suitable for resistant hypertension Convenient once-daily dosing Suitable for long-term hypertension management under medical supervision Clinical Applications MND-0.3 is commonly prescribed for essential hypertension, resistant hypertension, hypertension with metabolic syndrome, hypertension with obesity, hypertension with diabetes mellitus, hypertension with chronic kidney disease, and long-term cardiovascular risk reduction. Facts About Moxonidine Moxonidine is a selective imidazoline receptor agonist with proven efficacy in reducing blood pressure through central sympathetic inhibition. It is particularly valuable in patients with metabolic syndrome, obesity, insulin resistance, and increased sympathetic activity. Clinical studies have demonstrated effective blood pressure reduction with favorable metabolic and autonomic effects. Key Facts Selective imidazoline I1 receptor agonist Moxonidine 0.3 mg for sympathetic blood pressure control Reduces central sympathetic activity May improve insulin sensitivity Favorable metabolic and cardiovascular profile Evidence-based antihypertensive therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity MND-0.3 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, obesity, metabolic syndrome, and cardiovascular disorders creates strong prescription demand and long-term market potential for this formulation. Why Choose MND-0.3 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Moxonidine 0.3 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented formulation Moisture-controlled tablet manufacturing Blister and Alu-Alu packaging options MND-0.3 from DIABGLYM combines effective blood pressure control, sympathetic modulation, favorable metabolic benefits, evidence-based cardiovascular therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Moxonidine formulation.

NEBROOT-2.5 Nebivolol 2.5 mg Tablets Division: DIABGLYM Composition Each tablet contains: Nebivolol IP — 2.5 mg Excipients — q.s. Colour: Approved colour used Dosage form: Oral tablet Product Description NEBROOT-2.5 contains Nebivolol 2.5 mg, a third-generation highly selective beta-1 adrenergic receptor blocker formulated for the effective management of hypertension and long-term cardiovascular protection. Nebivolol offers a unique combination of beta-1 selective blockade and nitric oxide-mediated vasodilatory action, resulting in effective blood pressure reduction with improved endothelial function and vascular protection. Nebivolol is widely prescribed in cardiology and internal medicine for patients with essential hypertension, coronary artery disease, heart failure, diabetes-associated hypertension, and cardiovascular risk reduction. It helps reduce heart rate, myocardial oxygen demand, cardiac workload, and peripheral vascular resistance while maintaining excellent tolerability and a favorable metabolic profile. NEBROOT-2.5 is particularly beneficial for patients initiating beta-blocker therapy, elderly hypertensive patients, individuals requiring low-dose antihypertensive treatment, hypertension associated with tachycardia, and patients requiring long-term beta-blocker therapy with vascular protective benefits. Technical Knowledge of Nebivolol Nebivolol selectively blocks beta-1 adrenergic receptors in the heart, reducing sympathetic stimulation, heart rate, myocardial contractility, and renin secretion. In addition to beta-blockade, Nebivolol stimulates endothelial nitric oxide release, producing vasodilation, improved endothelial function, enhanced arterial compliance, and reduced peripheral vascular resistance. Unlike many traditional beta-blockers, Nebivolol has minimal adverse effects on glucose metabolism, lipid profile, and exercise tolerance, making it particularly suitable for patients with diabetes, metabolic syndrome, and cardiovascular comorbidities. Mechanism of Action Nebivolol selectively blocks beta-1 receptors, reduces heart rate and myocardial contractility, decreases cardiac output, suppresses renin release, stimulates nitric oxide-mediated vasodilation, improves endothelial function, and reduces peripheral vascular resistance. Key Benefits Effective reduction of systolic and diastolic blood pressure Reduces heart rate and myocardial workload Improves endothelial function Provides nitric oxide-mediated vasodilation Supports cardiovascular protection Favorable metabolic profile Suitable for low-dose antihypertensive therapy Convenient once-daily dosing Suitable for long-term hypertension management under medical supervision Clinical Applications NEBROOT-2.5 is commonly prescribed for essential hypertension, hypertension with tachycardia, hypertension with coronary artery disease, hypertension with diabetes mellitus, metabolic syndrome, chronic heart failure, left ventricular dysfunction, elderly hypertension, and long-term cardiovascular risk reduction. Facts About Nebivolol Nebivolol is a modern third-generation beta-blocker with unique nitric oxide-mediated vasodilatory properties that distinguish it from conventional beta-blockers. Extensive clinical evidence demonstrates effective blood pressure reduction, improvement in endothelial function, and favorable cardiovascular outcomes. The 2.5 mg strength is particularly useful for therapy initiation, elderly patients, and patients requiring individualized dose titration. Key Facts Third-generation highly selective beta-1 blocker Nebivolol 2.5 mg for blood pressure and heart rate control Nitric oxide-mediated vasodilatory action Improves endothelial function and vascular health Favorable metabolic and cardiovascular profile Evidence-based antihypertensive and cardioprotective therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity NEBROOT-2.5 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, coronary artery disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this formulation. Why Choose NEBROOT-2.5 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Nebivolol 2.5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented formulation Moisture-controlled tablet manufacturing Blister and Alu-Alu packaging options NEBROOT-2.5 from DIABGLYM combines effective blood pressure control, heart rate management, endothelial protection, evidence-based cardiovascular therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Nebivolol formulation.

NEBROOT-H 5 Nebivolol 5 mg and Telmisartan 40 mg Tablets Division: DIABGLYM Composition Each tablet contains: Nebivolol IP — 5 mg Telmisartan IP — 40 mg Excipients — q.s. Colour: Approved colour used Dosage form: Oral tablet Product Description NEBROOT-H 5 is a scientifically balanced antihypertensive combination of Nebivolol 5 mg and Telmisartan 40 mg, formulated for the effective management of hypertension and long-term cardiovascular protection. This combination provides dual blood pressure control by combining the highly selective beta-1 blocking and nitric oxide-mediated vasodilatory effects of Nebivolol with the renin-angiotensin system blockade of Telmisartan, resulting in superior antihypertensive efficacy and enhanced cardiovascular and renal protection. Nebivolol is a third-generation beta-1 selective blocker with additional nitric oxide-mediated vasodilatory properties that helps reduce heart rate, myocardial oxygen demand, and vascular resistance while improving endothelial function. Telmisartan is a long-acting angiotensin II receptor blocker (ARB) that promotes vasodilation, reduces peripheral vascular resistance, provides cardiovascular and renal protection, and has favorable metabolic effects. NEBROOT-H 5 is particularly beneficial in patients with hypertension associated with tachycardia, diabetes, chronic kidney disease, coronary artery disease, metabolic syndrome, obesity, and patients requiring combination antihypertensive therapy with heart rate control. Technical Knowledge of Nebivolol and Telmisartan Nebivolol selectively blocks beta-1 adrenergic receptors in the heart and stimulates endothelial nitric oxide release, producing vasodilation, reduced heart rate, decreased myocardial contractility, improved endothelial function, enhanced vascular compliance, and reduced peripheral vascular resistance. Telmisartan selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction, aldosterone secretion, sympathetic activation, and vascular remodeling. Telmisartan also exhibits partial PPAR-gamma agonistic activity, which may contribute to favorable metabolic effects in patients with insulin resistance and metabolic syndrome. The combination of Nebivolol and Telmisartan provides complementary antihypertensive mechanisms with additional cardiovascular, renal, and endothelial protective benefits. Mechanism of Action Nebivolol selectively blocks beta-1 receptors, reduces heart rate and myocardial contractility, stimulates nitric oxide-mediated vasodilation, improves endothelial function, decreases peripheral vascular resistance, and reduces myocardial oxygen demand. Telmisartan blocks AT1 receptors, promotes vasodilation, reduces peripheral vascular resistance, decreases aldosterone secretion, improves vascular function, and protects cardiovascular and renal tissues. Key Benefits Effective reduction of systolic and diastolic blood pressure Dual antihypertensive mechanism Provides sustained 24-hour blood pressure control Reduces heart rate and myocardial workload Supports cardiovascular and renal protection Improves endothelial function Favorable metabolic profile Convenient once-daily dosing Suitable for long-term hypertension management under medical supervision Clinical Applications NEBROOT-H 5 is commonly prescribed for essential hypertension, hypertension with tachycardia, hypertension with diabetes mellitus, hypertension with chronic kidney disease, hypertension with coronary artery disease, metabolic syndrome, obesity-associated hypertension, and long-term cardiovascular risk reduction. Facts About Nebivolol and Telmisartan Nebivolol is a modern beta-blocker with nitric oxide-mediated vasodilatory activity and excellent metabolic and endothelial profiles. Telmisartan is a long-acting ARB with proven cardiovascular and renal protective benefits and favorable effects on insulin sensitivity. The combination is particularly useful in hypertensive patients requiring both blood pressure reduction and heart rate control with comprehensive cardiovascular protection. Key Facts Beta-blocker and ARB combination therapy Nebivolol 5 mg for heart rate control and endothelial support Telmisartan 40 mg for vascular and renal protection Provides sustained 24-hour antihypertensive action Effective in hypertension with diabetes and chronic kidney disease Evidence-based cardiovascular combination therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity NEBROOT-H 5 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, coronary artery disease, chronic kidney disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination. Why Choose NEBROOT-H 5 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Nebivolol 5 mg and Telmisartan 40 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented formulation Moisture-controlled tablet manufacturing Blister and Alu-Alu packaging options NEBROOT-H 5 from DIABGLYM combines effective blood pressure control, heart rate management, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Nebivolol and Telmisartan formulation.

NEBROOT-5 Nebivolol 5 mg Tablets Division: DIABGLYM Composition Each tablet contains: Nebivolol IP — 5 mg Excipients — q.s. Colour: Approved colour used Dosage form: Oral tablet Product Description NEBROOT-5 contains Nebivolol 5 mg, a third-generation highly selective beta-1 adrenergic receptor blocker formulated for the effective management of hypertension and long-term cardiovascular protection. Nebivolol offers a unique combination of beta-1 selective blockade and nitric oxide-mediated vasodilatory action, resulting in effective blood pressure reduction with improved endothelial function and vascular protection. Nebivolol is widely prescribed in cardiology and internal medicine for patients with essential hypertension, coronary artery disease, heart failure, diabetes-associated hypertension, and cardiovascular risk reduction. It helps reduce heart rate, myocardial oxygen demand, cardiac workload, and peripheral vascular resistance while maintaining excellent tolerability and a favorable metabolic profile. NEBROOT-5 is particularly beneficial for patients with hypertension associated with tachycardia, ischemic heart disease, left ventricular dysfunction, metabolic syndrome, diabetes, and patients requiring long-term beta-blocker therapy with vascular protective benefits. Technical Knowledge of Nebivolol Nebivolol selectively blocks beta-1 adrenergic receptors in the heart, reducing sympathetic stimulation, heart rate, myocardial contractility, and renin secretion. In addition to beta-blockade, Nebivolol stimulates endothelial nitric oxide release, producing vasodilation, improved endothelial function, enhanced arterial compliance, and reduced peripheral vascular resistance. Unlike many traditional beta-blockers, Nebivolol has minimal adverse effects on glucose metabolism, lipid profile, and exercise tolerance, making it particularly suitable for patients with diabetes, metabolic syndrome, and cardiovascular comorbidities. Mechanism of Action Nebivolol selectively blocks beta-1 receptors, reduces heart rate and myocardial contractility, decreases cardiac output, suppresses renin release, stimulates nitric oxide-mediated vasodilation, improves endothelial function, and reduces peripheral vascular resistance. Key Benefits Effective reduction of systolic and diastolic blood pressure Reduces heart rate and myocardial workload Improves endothelial function Provides nitric oxide-mediated vasodilation Supports cardiovascular protection Favorable metabolic profile Convenient once-daily dosing Suitable for long-term hypertension management under medical supervision Clinical Applications NEBROOT-5 is commonly prescribed for essential hypertension, hypertension with tachycardia, hypertension with coronary artery disease, hypertension with diabetes mellitus, metabolic syndrome, chronic heart failure, left ventricular dysfunction, and long-term cardiovascular risk reduction. Facts About Nebivolol Nebivolol is a modern third-generation beta-blocker with unique nitric oxide-mediated vasodilatory properties that distinguish it from conventional beta-blockers. Extensive clinical evidence demonstrates effective blood pressure reduction, improvement in endothelial function, and favorable cardiovascular outcomes. Its excellent tolerability and metabolic neutrality make it an important therapeutic option in contemporary hypertension management. Key Facts Third-generation highly selective beta-1 blocker Nebivolol 5 mg for blood pressure and heart rate control Nitric oxide-mediated vasodilatory action Improves endothelial function and vascular health Favorable metabolic and cardiovascular profile Evidence-based antihypertensive and cardioprotective therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity NEBROOT-5 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, coronary artery disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this formulation. Why Choose NEBROOT-5 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Nebivolol 5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented formulation Moisture-controlled tablet manufacturing Blister and Alu-Alu packaging options NEBROOT-5 from DIABGLYM combines effective blood pressure control, heart rate management, endothelial protection, evidence-based cardiovascular therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Nebivolol formulation.

NEBROOT-AM Nebivolol 5 mg and S(-) Amlodipine 5 mg Tablets Division: DIABGLYM Composition Each tablet contains: Nebivolol IP — 5 mg S(-) Amlodipine IP — 5 mg Excipients — q.s. Colour: Approved colour used Dosage form: Oral tablet Product Description NEBROOT-AM is a scientifically balanced antihypertensive combination of Nebivolol 5 mg and S(-) Amlodipine 5 mg, formulated for the effective management of hypertension and long-term cardiovascular protection. This combination provides dual blood pressure control by combining the highly selective beta-1 blocking and nitric oxide-mediated vasodilatory effects of Nebivolol with the sustained vasodilatory action of S(-) Amlodipine, resulting in superior antihypertensive efficacy and improved cardiovascular outcomes. Nebivolol is a third-generation beta-1 selective blocker with additional nitric oxide-mediated vasodilatory properties that helps reduce heart rate, myocardial oxygen demand, and vascular resistance while improving endothelial function. S(-) Amlodipine is the pharmacologically active isomer of amlodipine that provides effective arterial vasodilation with improved efficacy and a lower incidence of peripheral edema compared with conventional racemic amlodipine. NEBROOT-AM is particularly beneficial in patients with hypertension associated with tachycardia, coronary artery disease, diabetes, metabolic syndrome, elderly hypertension, and patients requiring combination antihypertensive therapy with heart rate control. Technical Knowledge of Nebivolol and S(-) Amlodipine Nebivolol selectively blocks beta-1 adrenergic receptors in the heart and stimulates endothelial nitric oxide release, producing vasodilation, reduced heart rate, decreased myocardial contractility, improved endothelial function, and enhanced vascular compliance. S(-) Amlodipine selectively inhibits L-type calcium channels in vascular smooth muscle, producing sustained arterial vasodilation, reducing peripheral vascular resistance, improving vascular compliance, and maintaining stable blood pressure control throughout the dosing interval. The combination of Nebivolol and S(-) Amlodipine provides complementary antihypertensive mechanisms with additional cardiovascular and endothelial protective benefits. Mechanism of Action Nebivolol selectively blocks beta-1 receptors, reduces heart rate and myocardial contractility, stimulates nitric oxide-mediated vasodilation, improves endothelial function, decreases peripheral vascular resistance, and reduces myocardial oxygen demand. S(-) Amlodipine blocks L-type calcium channels, relaxes vascular smooth muscle, reduces arterial resistance, improves vascular compliance, enhances coronary blood flow, and provides sustained antihypertensive action. Key Benefits Effective reduction of systolic and diastolic blood pressure Dual antihypertensive mechanism Provides sustained 24-hour blood pressure control Reduces heart rate and myocardial workload Supports cardiovascular protection Improves endothelial function Enhances vascular compliance May reduce the incidence of peripheral edema Suitable for long-term hypertension management under medical supervision Clinical Applications NEBROOT-AM is commonly prescribed for essential hypertension, hypertension with tachycardia, hypertension with coronary artery disease, hypertension with diabetes mellitus, metabolic syndrome, elderly hypertension, and long-term cardiovascular risk reduction. Facts About Nebivolol and S(-) Amlodipine Nebivolol is a modern beta-blocker with nitric oxide-mediated vasodilatory activity and excellent metabolic and endothelial profiles. S(-) Amlodipine is the active isomer responsible for the therapeutic antihypertensive effect of amlodipine and is associated with effective blood pressure control and improved tolerability. The combination is particularly useful in hypertensive patients requiring both blood pressure reduction and heart rate control. Key Facts Beta-blocker and calcium channel blocker combination therapy Nebivolol 5 mg for heart rate control and endothelial support S(-) Amlodipine 5 mg for sustained arterial vasodilation Provides comprehensive blood pressure and heart rate control Effective in hypertension with coronary artery disease and diabetes Evidence-based cardiovascular combination therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity NEBROOT-AM is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, coronary artery disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination. Why Choose NEBROOT-AM for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Nebivolol 5 mg and S(-) Amlodipine 5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented formulation Moisture-controlled tablet manufacturing Blister and Alu-Alu packaging options NEBROOT-AM from DIABGLYM combines effective blood pressure control, heart rate management, comprehensive cardiovascular protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Nebivolol and S(-) Amlodipine formulation.

NABROOT-CL 2.5 Cilnidipine 10 mg and Nebivolol 2.5 mg Tablets Division: DIABGLYM Composition Each tablet contains: Cilnidipine IP — 10 mg Nebivolol IP — 2.5 mg Excipients — q.s. Colour: Approved colour used Dosage form: Oral tablet Product Description NABROOT-CL 2.5 is a scientifically balanced antihypertensive combination of Cilnidipine 10 mg and Nebivolol 2.5 mg, formulated for the effective management of hypertension and long-term cardiovascular protection. This combination provides dual blood pressure control by combining the advanced calcium channel blocking action of Cilnidipine with the highly selective beta-1 blocking and nitric oxide-mediated vasodilatory effects of Nebivolol, resulting in superior antihypertensive efficacy and improved cardiovascular outcomes. Cilnidipine is a unique dual L-type and N-type calcium channel blocker that reduces peripheral vascular resistance, suppresses sympathetic overactivity, improves renal hemodynamics, and minimizes reflex tachycardia. Nebivolol is a third-generation beta-1 selective blocker with additional nitric oxide-mediated vasodilatory properties that helps reduce heart rate, myocardial oxygen demand, and vascular resistance while improving endothelial function. NABROOT-CL 2.5 is particularly beneficial in patients with hypertension associated with tachycardia, diabetes, chronic kidney disease, coronary artery disease, metabolic syndrome, elderly hypertension, and patients requiring lower-dose beta-blocker therapy with combination antihypertensive treatment. Technical Knowledge of Cilnidipine and Nebivolol Cilnidipine blocks both L-type calcium channels in vascular smooth muscle and N-type calcium channels in sympathetic nerve terminals. This dual mechanism reduces arterial vasoconstriction while decreasing sympathetic neurotransmitter release, resulting in sustained blood pressure reduction, improved renal perfusion, and reduced glomerular hypertension. Nebivolol selectively blocks beta-1 adrenergic receptors in the heart and stimulates endothelial nitric oxide release, producing vasodilation, reduced heart rate, decreased myocardial contractility, improved endothelial function, and enhanced vascular compliance. The combination of Cilnidipine and Nebivolol provides complementary antihypertensive mechanisms with additional cardiovascular, renal, and endothelial protective benefits. Mechanism of Action Cilnidipine blocks L-type and N-type calcium channels, relaxes vascular smooth muscle, suppresses sympathetic activity, improves renal blood flow, reduces glomerular pressure, and provides sustained antihypertensive action. Nebivolol selectively blocks beta-1 receptors, reduces heart rate and myocardial contractility, stimulates nitric oxide-mediated vasodilation, improves endothelial function, decreases peripheral vascular resistance, and reduces myocardial oxygen demand. Key Benefits Effective reduction of systolic and diastolic blood pressure Dual antihypertensive mechanism Provides sustained blood pressure control Reduces heart rate and myocardial workload Supports cardiovascular and renal protection Improves endothelial function Reduces sympathetic overactivity Minimizes reflex tachycardia Suitable for long-term hypertension management under medical supervision Clinical Applications NABROOT-CL 2.5 is commonly prescribed for essential hypertension, hypertension with tachycardia, hypertension with diabetes mellitus, hypertension with chronic kidney disease, hypertension with coronary artery disease, metabolic syndrome, elderly hypertension, and long-term cardiovascular risk reduction. Facts About Cilnidipine and Nebivolol Cilnidipine is an advanced calcium channel blocker with dual L-type and N-type channel blocking properties, providing effective blood pressure control with favorable renal and sympathetic modulation effects. Nebivolol is a modern beta-blocker with nitric oxide-mediated vasodilatory activity and excellent metabolic and endothelial profiles. The combination is particularly useful in hypertensive patients requiring both blood pressure reduction and heart rate control with a lower beta-blocker dose. Key Facts Dual calcium channel blocker and beta-blocker combination therapy Cilnidipine 10 mg for vascular and renal protection Nebivolol 2.5 mg for heart rate control and endothelial support Provides sustained antihypertensive action Effective in hypertension with tachycardia and diabetes Evidence-based cardiovascular combination therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity NABROOT-CL 2.5 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, coronary artery disease, chronic kidney disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination. Why Choose NABROOT-CL 2.5 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Cilnidipine 10 mg and Nebivolol 2.5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented formulation Moisture-controlled tablet manufacturing Blister and Alu-Alu packaging options NABROOT-CL 2.5 from DIABGLYM combines effective blood pressure control, heart rate management, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Cilnidipine and Nebivolol formulation.

NEBROOT-CL 5/10 Cilnidipine 10 mg and Nebivolol 5 mg Tablets Division: DIABGLYM Composition Each tablet contains: Cilnidipine IP — 10 mg Nebivolol IP — 5 mg Excipients — q.s. Colour: Approved colour used Dosage form: Oral tablet Product Description NEBROOT-CL 5/10 is a scientifically balanced antihypertensive combination of Cilnidipine 10 mg and Nebivolol 5 mg, formulated for the effective management of hypertension and long-term cardiovascular protection. This combination provides dual blood pressure control by combining the advanced calcium channel blocking action of Cilnidipine with the highly selective beta-1 blocking and nitric oxide-mediated vasodilatory effects of Nebivolol, resulting in superior antihypertensive efficacy and improved cardiovascular outcomes. Cilnidipine is a unique dual L-type and N-type calcium channel blocker that reduces peripheral vascular resistance, suppresses sympathetic overactivity, improves renal hemodynamics, and minimizes reflex tachycardia. Nebivolol is a third-generation beta-1 selective blocker with additional nitric oxide-mediated vasodilatory properties that helps reduce heart rate, myocardial oxygen demand, and vascular resistance while improving endothelial function. NEBROOT-CL 5/10 is particularly beneficial in patients with hypertension associated with tachycardia, diabetes, chronic kidney disease, coronary artery disease, metabolic syndrome, and patients requiring combination antihypertensive therapy with heart rate control. Technical Knowledge of Cilnidipine and Nebivolol Cilnidipine blocks both L-type calcium channels in vascular smooth muscle and N-type calcium channels in sympathetic nerve terminals. This dual mechanism reduces arterial vasoconstriction while decreasing sympathetic neurotransmitter release, resulting in sustained blood pressure reduction, improved renal perfusion, and reduced glomerular hypertension. Nebivolol selectively blocks beta-1 adrenergic receptors in the heart and stimulates endothelial nitric oxide release, producing vasodilation, reduced heart rate, decreased myocardial contractility, improved endothelial function, and enhanced vascular compliance. The combination of Cilnidipine and Nebivolol provides complementary antihypertensive mechanisms with additional cardiovascular, renal, and endothelial protective benefits. Mechanism of Action Cilnidipine blocks L-type and N-type calcium channels, relaxes vascular smooth muscle, suppresses sympathetic activity, improves renal blood flow, reduces glomerular pressure, and provides sustained antihypertensive action. Nebivolol selectively blocks beta-1 receptors, reduces heart rate and myocardial contractility, stimulates nitric oxide-mediated vasodilation, improves endothelial function, decreases peripheral vascular resistance, and reduces myocardial oxygen demand. Key Benefits Effective reduction of systolic and diastolic blood pressure Dual antihypertensive mechanism Provides sustained 24-hour blood pressure control Reduces heart rate and myocardial workload Supports cardiovascular and renal protection Improves endothelial function Reduces sympathetic overactivity Minimizes reflex tachycardia Suitable for long-term hypertension management under medical supervision Clinical Applications NEBROOT-CL 5/10 is commonly prescribed for essential hypertension, hypertension with tachycardia, hypertension with diabetes mellitus, hypertension with chronic kidney disease, hypertension with coronary artery disease, metabolic syndrome, elderly hypertension, and long-term cardiovascular risk reduction. Facts About Cilnidipine and Nebivolol Cilnidipine is an advanced calcium channel blocker with dual L-type and N-type channel blocking properties, providing effective blood pressure control with favorable renal and sympathetic modulation effects. Nebivolol is a modern beta-blocker with nitric oxide-mediated vasodilatory activity and excellent metabolic and endothelial profiles. The combination is particularly useful in hypertensive patients requiring both blood pressure reduction and heart rate control. Key Facts Dual calcium channel blocker and beta-blocker combination therapy Cilnidipine 10 mg for vascular and renal protection Nebivolol 5 mg for heart rate control and endothelial support Provides sustained 24-hour antihypertensive action Effective in hypertension with tachycardia and diabetes Evidence-based cardiovascular combination therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity NEBROOT-CL 5/10 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, coronary artery disease, chronic kidney disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination. Why Choose NEBROOT-CL 5/10 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Cilnidipine 10 mg and Nebivolol 5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented formulation Moisture-controlled tablet manufacturing Blister and Alu-Alu packaging options NEBROOT-CL 5/10 from DIABGLYM combines effective blood pressure control, heart rate management, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Cilnidipine and Nebivolol formulation.

NICOROOT-5 Nicorandil 5 mg Tablets Division: DIABGLYM Composition Each tablet contains: Nicorandil IP — 5 mg Excipients — q.s. Colour: Approved colour used Dosage form: Oral tablet Product Description NICOROOT-5 contains Nicorandil 5 mg, an advanced anti-anginal medication formulated for the prevention and long-term management of chronic stable angina pectoris and ischemic heart disease. Nicorandil possesses a unique dual mechanism of action by acting as both a nitrate donor and an ATP-sensitive potassium (KATP) channel opener, resulting in balanced arterial and venous vasodilation, improved coronary blood flow, and reduced myocardial oxygen demand. Nicorandil is widely prescribed in cardiology for patients with chronic coronary artery disease, recurrent angina, microvascular angina, and patients who continue to experience anginal symptoms despite conventional anti-anginal therapy. It helps reduce the frequency of angina attacks, improve exercise tolerance, enhance myocardial perfusion, and decrease nitrate requirements. NICOROOT-5 is particularly beneficial for patients initiating Nicorandil therapy, elderly patients, those requiring low-dose anti-anginal treatment, improved coronary circulation, and additional anti-ischemic protection without significant negative effects on cardiac contractility. Technical Knowledge of Nicorandil Nicorandil combines nitrate-like vasodilatory properties with ATP-sensitive potassium channel activation. The nitrate component increases nitric oxide availability, activates guanylate cyclase, increases cyclic GMP levels, and relaxes vascular smooth muscle. The KATP channel opening effect causes hyperpolarization of vascular smooth muscle cells, producing additional arterial vasodilation and improved coronary microvascular circulation. This dual mechanism reduces preload and afterload, improves coronary artery perfusion, enhances myocardial oxygen supply, and decreases myocardial oxygen consumption. Nicorandil also has favorable effects on coronary microcirculation and ischemic myocardial protection. Mechanism of Action Nicorandil releases nitric oxide, activates guanylate cyclase, increases cyclic GMP levels, opens ATP-sensitive potassium channels, relaxes vascular smooth muscle, dilates coronary and peripheral arteries, reduces preload and afterload, improves myocardial perfusion, and decreases myocardial oxygen demand. Key Benefits Helps prevent chronic angina attacks Improves coronary blood flow and microcirculation Reduces myocardial oxygen demand Enhances exercise tolerance Decreases frequency of anginal episodes Provides dual anti-anginal mechanism Supports long-term ischemic heart disease management Suitable for chronic anti-anginal therapy under medical supervision Clinical Applications NICOROOT-5 is commonly prescribed for chronic stable angina pectoris, coronary artery disease, ischemic heart disease, refractory angina, microvascular angina, long-term anti-anginal therapy, prevention of recurrent angina episodes, and patients requiring low-dose anti-anginal treatment. Facts About Nicorandil Nicorandil is a unique anti-anginal agent with both nitrate-donor and potassium channel opening properties. It has demonstrated efficacy in improving angina symptoms, exercise capacity, and coronary perfusion, and is particularly useful in patients with persistent angina despite standard anti-anginal therapy. The 5 mg strength is commonly used for therapy initiation, elderly patients, and patients requiring individualized dose titration and long-term anti-anginal management. Key Facts Dual-mechanism anti-anginal therapy Nicorandil 5 mg for sustained angina prevention Nitrate donor and potassium channel opener Improves coronary blood flow and microvascular circulation Reduces myocardial oxygen demand Evidence-based cardiovascular therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity NICOROOT-5 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of coronary artery disease, chronic angina, diabetes, hypertension, and ischemic heart disease creates strong prescription demand and long-term market potential for this formulation. Why Choose NICOROOT-5 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Nicorandil 5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented formulation Moisture-controlled tablet manufacturing Blister and Alu-Alu packaging options NICOROOT-5 from DIABGLYM combines advanced dual-mechanism anti-anginal therapy, improved coronary perfusion, evidence-based cardiovascular care, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Nicorandil formulation.

NICOROOT-10 Nicorandil 10 mg Tablets Division: DIABGLYM Composition Each tablet contains: Nicorandil IP — 10 mg Excipients — q.s. Colour: Approved colour used Dosage form: Oral tablet Product Description NICOROOT-10 contains Nicorandil 10 mg, an advanced anti-anginal medication formulated for the prevention and long-term management of chronic stable angina pectoris and ischemic heart disease. Nicorandil possesses a unique dual mechanism of action by acting as both a nitrate donor and an ATP-sensitive potassium (KATP) channel opener, resulting in balanced arterial and venous vasodilation, improved coronary blood flow, and reduced myocardial oxygen demand. Nicorandil is widely prescribed in cardiology for patients with chronic coronary artery disease, recurrent angina, microvascular angina, and patients who continue to experience anginal symptoms despite conventional anti-anginal therapy. It helps reduce the frequency of angina attacks, improve exercise tolerance, enhance myocardial perfusion, and decrease nitrate requirements. NICOROOT-10 is particularly beneficial for patients initiating Nicorandil therapy, those requiring moderate-dose anti-anginal treatment, improved coronary circulation, and additional anti-ischemic protection without significant negative effects on cardiac contractility. Technical Knowledge of Nicorandil Nicorandil combines nitrate-like vasodilatory properties with ATP-sensitive potassium channel activation. The nitrate component increases nitric oxide availability, activates guanylate cyclase, increases cyclic GMP levels, and relaxes vascular smooth muscle. The KATP channel opening effect causes hyperpolarization of vascular smooth muscle cells, producing additional arterial vasodilation and improved coronary microvascular circulation. This dual mechanism reduces preload and afterload, improves coronary artery perfusion, enhances myocardial oxygen supply, and decreases myocardial oxygen consumption. Nicorandil also has favorable effects on coronary microcirculation and ischemic myocardial protection. Mechanism of Action Nicorandil releases nitric oxide, activates guanylate cyclase, increases cyclic GMP levels, opens ATP-sensitive potassium channels, relaxes vascular smooth muscle, dilates coronary and peripheral arteries, reduces preload and afterload, improves myocardial perfusion, and decreases myocardial oxygen demand. Key Benefits Helps prevent chronic angina attacks Improves coronary blood flow and microcirculation Reduces myocardial oxygen demand Enhances exercise tolerance Decreases frequency of anginal episodes Provides dual anti-anginal mechanism Supports long-term ischemic heart disease management Suitable for chronic anti-anginal therapy under medical supervision Clinical Applications NICOROOT-10 is commonly prescribed for chronic stable angina pectoris, coronary artery disease, ischemic heart disease, refractory angina, microvascular angina, long-term anti-anginal therapy, prevention of recurrent angina episodes, and patients requiring moderate-dose anti-anginal treatment. Facts About Nicorandil Nicorandil is a unique anti-anginal agent with both nitrate-donor and potassium channel opening properties. It has demonstrated efficacy in improving angina symptoms, exercise capacity, and coronary perfusion, and is particularly useful in patients with persistent angina despite standard anti-anginal therapy. The 10 mg strength is commonly used for initiation and maintenance therapy in patients requiring individualized long-term anti-anginal management. Key Facts Dual-mechanism anti-anginal therapy Nicorandil 10 mg for sustained angina prevention Nitrate donor and potassium channel opener Improves coronary blood flow and microvascular circulation Reduces myocardial oxygen demand Evidence-based cardiovascular therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity NICOROOT-10 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of coronary artery disease, chronic angina, diabetes, hypertension, and ischemic heart disease creates strong prescription demand and long-term market potential for this formulation. Why Choose NICOROOT-10 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Nicorandil 10 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented formulation Moisture-controlled tablet manufacturing Blister and Alu-Alu packaging options NICOROOT-10 from DIABGLYM combines advanced dual-mechanism anti-anginal therapy, improved coronary perfusion, evidence-based cardiovascular care, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Nicorandil formulation.

NICOROOT-20 Nicorandil 20 mg Tablets Division: DIABGLYM Composition Each tablet contains: Nicorandil IP — 20 mg Excipients — q.s. Colour: Approved colour used Dosage form: Oral tablet Product Description NICOROOT-20 contains Nicorandil 20 mg, an advanced anti-anginal medication formulated for the prevention and long-term management of chronic stable angina pectoris and ischemic heart disease. Nicorandil possesses a unique dual mechanism of action by acting as both a nitrate donor and an ATP-sensitive potassium (KATP) channel opener, resulting in balanced arterial and venous vasodilation, improved coronary blood flow, and reduced myocardial oxygen demand. Nicorandil is widely prescribed in cardiology for patients with chronic coronary artery disease, recurrent angina, microvascular angina, and patients who continue to experience anginal symptoms despite conventional anti-anginal therapy. It helps reduce the frequency of angina attacks, improve exercise tolerance, enhance myocardial perfusion, and decrease nitrate requirements. NICOROOT-20 is particularly beneficial for patients requiring long-term anti-anginal therapy, improved coronary circulation, and additional anti-ischemic protection without significant negative effects on cardiac contractility. Technical Knowledge of Nicorandil Nicorandil combines nitrate-like vasodilatory properties with ATP-sensitive potassium channel activation. The nitrate component increases nitric oxide availability, activates guanylate cyclase, increases cyclic GMP levels, and relaxes vascular smooth muscle. The KATP channel opening effect causes hyperpolarization of vascular smooth muscle cells, producing additional arterial vasodilation and improved coronary microvascular circulation. This dual mechanism reduces preload and afterload, improves coronary artery perfusion, enhances myocardial oxygen supply, and decreases myocardial oxygen consumption. Nicorandil also has favorable effects on coronary microcirculation and ischemic myocardial protection. Mechanism of Action Nicorandil releases nitric oxide, activates guanylate cyclase, increases cyclic GMP levels, opens ATP-sensitive potassium channels, relaxes vascular smooth muscle, dilates coronary and peripheral arteries, reduces preload and afterload, improves myocardial perfusion, and decreases myocardial oxygen demand. Key Benefits Helps prevent chronic angina attacks Improves coronary blood flow and microcirculation Reduces myocardial oxygen demand Enhances exercise tolerance Decreases frequency of anginal episodes Provides dual anti-anginal mechanism Supports long-term ischemic heart disease management Suitable for chronic anti-anginal therapy under medical supervision Clinical Applications NICOROOT-20 is commonly prescribed for chronic stable angina pectoris, coronary artery disease, ischemic heart disease, refractory angina, microvascular angina, long-term anti-anginal therapy, and prevention of recurrent angina episodes. Facts About Nicorandil Nicorandil is a unique anti-anginal agent with both nitrate-donor and potassium channel opening properties. It has demonstrated efficacy in improving angina symptoms, exercise capacity, and coronary perfusion, and is particularly useful in patients with persistent angina despite standard anti-anginal therapy. Its beneficial effects on coronary microcirculation make it an important therapeutic option in chronic ischemic heart disease. Key Facts Dual-mechanism anti-anginal therapy Nicorandil 20 mg for sustained angina prevention Nitrate donor and potassium channel opener Improves coronary blood flow and microvascular circulation Reduces myocardial oxygen demand Evidence-based cardiovascular therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity NICOROOT-20 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of coronary artery disease, chronic angina, diabetes, hypertension, and ischemic heart disease creates strong prescription demand and long-term market potential for this formulation. Why Choose NICOROOT-20 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Nicorandil 20 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented formulation Moisture-controlled tablet manufacturing Blister and Alu-Alu packaging options NICOROOT-20 from DIABGLYM combines advanced dual-mechanism anti-anginal therapy, improved coronary perfusion, evidence-based cardiovascular care, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Nicorandil formulation.

NIFEROOT-10 Nifedipine Sustained Release 10 mg Tablets Division: DIABGLYM Composition Each sustained-release tablet contains: Nifedipine IP — 10 mg Excipients — q.s. Colour: Approved colour used Dosage form: Sustained-release oral tablet Product Description NIFEROOT-10 contains Nifedipine Sustained Release 10 mg, a long-acting dihydropyridine calcium channel blocker formulated for the effective management of hypertension, chronic stable angina, vasospastic angina, and long-term cardiovascular risk reduction. The sustained-release formulation provides gradual drug release, ensuring prolonged blood pressure control, improved coronary blood flow, and reduced cardiovascular workload. Nifedipine is widely prescribed in cardiology and internal medicine for patients with essential hypertension, isolated systolic hypertension, coronary artery disease, and peripheral vascular disorders. It helps reduce systolic and diastolic blood pressure, improve myocardial oxygen supply, decrease peripheral vascular resistance, and lower the risk of cardiovascular complications. NIFEROOT-10 is particularly beneficial for patients initiating sustained-release nifedipine therapy, elderly hypertensive patients, individuals requiring low-dose antihypertensive treatment, angina prophylaxis, and long-term cardiovascular protection. Technical Knowledge of Nifedipine Sustained Release Nifedipine selectively inhibits L-type calcium channels in vascular smooth muscle and coronary arteries. By reducing calcium influx into vascular smooth muscle cells, it produces arterial vasodilation, decreases peripheral vascular resistance, improves coronary artery blood flow, and reduces myocardial oxygen demand. The sustained-release formulation provides controlled drug delivery over an extended period, maintaining stable plasma concentrations and minimizing fluctuations associated with immediate-release formulations. This results in prolonged antihypertensive efficacy and improved tolerability. Mechanism of Action Nifedipine blocks L-type calcium channels, relaxes vascular smooth muscle, dilates peripheral and coronary arteries, reduces systemic vascular resistance, lowers blood pressure, improves coronary perfusion, and decreases myocardial oxygen demand. Key Benefits Effective reduction of systolic and diastolic blood pressure Provides sustained blood pressure control Improves coronary blood flow Reduces peripheral vascular resistance Helps prevent chronic angina attacks Supports long-term cardiovascular protection Suitable for low-dose antihypertensive therapy Convenient sustained-release dosing Suitable for long-term hypertension and angina management under medical supervision Clinical Applications NIFEROOT-10 is commonly prescribed for essential hypertension, isolated systolic hypertension, chronic stable angina, vasospastic angina, coronary artery disease, peripheral vascular disorders, elderly hypertension, and long-term cardiovascular risk reduction. Facts About Nifedipine Nifedipine is one of the most extensively studied calcium channel blockers and has proven efficacy in hypertension and chronic angina management. Sustained-release formulations provide prolonged therapeutic activity, improved patient adherence, and more stable blood pressure control. The 10 mg sustained-release strength is particularly useful for therapy initiation, elderly patients, and individuals requiring gradual dose titration. Key Facts Long-acting calcium channel blocker Nifedipine Sustained Release 10 mg for low-dose blood pressure control Provides prolonged coronary vasodilation Effective in hypertension and chronic angina Supports long-term cardiovascular protection Evidence-based calcium channel blocker therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity NIFEROOT-10 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, coronary artery disease, diabetes, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this formulation. Why Choose NIFEROOT-10 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Nifedipine Sustained Release 10 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented sustained-release formulation Controlled-release tablet manufacturing technology Blister and Alu-Alu packaging options NIFEROOT-10 from DIABGLYM combines sustained blood pressure control, improved coronary perfusion, evidence-based cardiovascular therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Nifedipine sustained-release formulation.

NIFEROOT-20 Nifedipine Sustained Release 20 mg Tablets Division: DIABGLYM Composition Each sustained-release tablet contains: Nifedipine IP — 20 mg Excipients — q.s. Colour: Approved colour used Dosage form: Sustained-release oral tablet Product Description NIFEROOT-20 contains Nifedipine Sustained Release 20 mg, a long-acting dihydropyridine calcium channel blocker formulated for the effective management of hypertension, chronic stable angina, vasospastic angina, and long-term cardiovascular risk reduction. The sustained-release formulation provides gradual drug release, ensuring prolonged blood pressure control, improved coronary blood flow, and reduced cardiovascular workload. Nifedipine is widely prescribed in cardiology and internal medicine for patients with essential hypertension, isolated systolic hypertension, coronary artery disease, and peripheral vascular disorders. It helps reduce systolic and diastolic blood pressure, improve myocardial oxygen supply, decrease peripheral vascular resistance, and lower the risk of cardiovascular complications. NIFEROOT-20 is particularly beneficial for patients initiating sustained-release nifedipine therapy, those requiring moderate-dose antihypertensive treatment, once-daily blood pressure control, angina prophylaxis, and long-term cardiovascular protection. Technical Knowledge of Nifedipine Sustained Release Nifedipine selectively inhibits L-type calcium channels in vascular smooth muscle and coronary arteries. By reducing calcium influx into vascular smooth muscle cells, it produces arterial vasodilation, decreases peripheral vascular resistance, improves coronary artery blood flow, and reduces myocardial oxygen demand. The sustained-release formulation provides controlled drug delivery over an extended period, maintaining stable plasma concentrations and minimizing fluctuations associated with immediate-release formulations. This results in prolonged antihypertensive efficacy and improved tolerability. Mechanism of Action Nifedipine blocks L-type calcium channels, relaxes vascular smooth muscle, dilates peripheral and coronary arteries, reduces systemic vascular resistance, lowers blood pressure, improves coronary perfusion, and decreases myocardial oxygen demand. Key Benefits Effective reduction of systolic and diastolic blood pressure Provides sustained 24-hour blood pressure control Improves coronary blood flow Reduces peripheral vascular resistance Helps prevent chronic angina attacks Supports long-term cardiovascular protection Convenient sustained-release dosing Suitable for long-term hypertension and angina management under medical supervision Clinical Applications NIFEROOT-20 is commonly prescribed for essential hypertension, isolated systolic hypertension, chronic stable angina, vasospastic angina, coronary artery disease, peripheral vascular disorders, and long-term cardiovascular risk reduction. Facts About Nifedipine Nifedipine is one of the most extensively studied calcium channel blockers and has proven efficacy in hypertension and chronic angina management. Sustained-release formulations provide prolonged therapeutic activity, improved patient adherence, and more stable blood pressure control. The 20 mg sustained-release strength is commonly used for initiation and maintenance therapy in patients requiring individualized antihypertensive treatment. Key Facts Long-acting calcium channel blocker Nifedipine Sustained Release 20 mg for sustained blood pressure control Provides prolonged coronary vasodilation Effective in hypertension and chronic angina Supports long-term cardiovascular protection Evidence-based calcium channel blocker therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity NIFEROOT-20 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, coronary artery disease, diabetes, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this formulation. Why Choose NIFEROOT-20 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Nifedipine Sustained Release 20 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented sustained-release formulation Controlled-release tablet manufacturing technology Blister and Alu-Alu packaging options NIFEROOT-20 from DIABGLYM combines sustained blood pressure control, improved coronary perfusion, evidence-based cardiovascular therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Nifedipine sustained-release formulation.

NIFEROOT-30 Nifedipine Sustained Release 30 mg Tablets Division: DIABGLYM Composition Each sustained-release tablet contains: Nifedipine IP — 30 mg Excipients — q.s. Colour: Approved colour used Dosage form: Sustained-release oral tablet Product Description NIFEROOT-30 contains Nifedipine Sustained Release 30 mg, a long-acting dihydropyridine calcium channel blocker formulated for the effective management of hypertension, chronic stable angina, vasospastic angina, and long-term cardiovascular risk reduction. The sustained-release formulation provides gradual drug release, ensuring prolonged blood pressure control, improved coronary blood flow, and reduced cardiovascular workload. Nifedipine is widely prescribed in cardiology and internal medicine for patients with essential hypertension, isolated systolic hypertension, coronary artery disease, and peripheral vascular disorders. It helps reduce systolic and diastolic blood pressure, improve myocardial oxygen supply, decrease peripheral vascular resistance, and lower the risk of cardiovascular complications. NIFEROOT-30 is particularly beneficial for patients requiring sustained antihypertensive therapy, once-daily blood pressure control, angina prophylaxis, and long-term cardiovascular protection. Technical Knowledge of Nifedipine Sustained Release Nifedipine selectively inhibits L-type calcium channels in vascular smooth muscle and coronary arteries. By reducing calcium influx into vascular smooth muscle cells, it produces arterial vasodilation, decreases peripheral vascular resistance, improves coronary artery blood flow, and reduces myocardial oxygen demand. The sustained-release formulation provides controlled drug delivery over an extended period, maintaining stable plasma concentrations and minimizing fluctuations associated with immediate-release formulations. This results in prolonged antihypertensive efficacy and improved tolerability. Mechanism of Action Nifedipine blocks L-type calcium channels, relaxes vascular smooth muscle, dilates peripheral and coronary arteries, reduces systemic vascular resistance, lowers blood pressure, improves coronary perfusion, and decreases myocardial oxygen demand. Key Benefits Effective reduction of systolic and diastolic blood pressure Provides sustained 24-hour blood pressure control Improves coronary blood flow Reduces peripheral vascular resistance Helps prevent chronic angina attacks Supports long-term cardiovascular protection Convenient sustained-release once-daily dosing Suitable for long-term hypertension and angina management under medical supervision Clinical Applications NIFEROOT-30 is commonly prescribed for essential hypertension, isolated systolic hypertension, chronic stable angina, vasospastic angina, coronary artery disease, peripheral vascular disorders, and long-term cardiovascular risk reduction. Facts About Nifedipine Nifedipine is one of the most extensively studied calcium channel blockers and has proven efficacy in hypertension and chronic angina management. Sustained-release formulations provide prolonged therapeutic activity, improved patient adherence, and more stable blood pressure control. Long-acting nifedipine preparations are widely recommended for chronic cardiovascular management. Key Facts Long-acting calcium channel blocker Nifedipine Sustained Release 30 mg for sustained blood pressure control Provides prolonged coronary vasodilation Effective in hypertension and chronic angina Supports long-term cardiovascular protection Evidence-based calcium channel blocker therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity NIFEROOT-30 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, coronary artery disease, diabetes, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this formulation. Why Choose NIFEROOT-30 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Nifedipine Sustained Release 30 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented sustained-release formulation Controlled-release tablet manufacturing technology Blister and Alu-Alu packaging options NIFEROOT-30 from DIABGLYM combines sustained blood pressure control, improved coronary perfusion, evidence-based cardiovascular therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Nifedipine sustained-release formulation.

NITROOT-2.6 Nitroglycerin Controlled Release 2.6 mg Tablets Division: DIABGLYM Composition Each controlled-release tablet contains: Nitroglycerin IP — 2.6 mg Excipients — q.s. Colour: Approved colour used Dosage form: Controlled-release oral tablet Product Description NITROOT-2.6 contains Nitroglycerin Controlled Release 2.6 mg, a long-acting nitrate formulation designed for the prevention and long-term management of chronic stable angina pectoris and ischemic heart disease. The controlled-release formulation provides sustained release of nitroglycerin, helping reduce the frequency of angina attacks, improve exercise tolerance, and decrease myocardial oxygen demand. Nitroglycerin is a well-established anti-anginal agent widely used in cardiology for patients with chronic coronary artery disease, recurrent angina, post-myocardial infarction ischemia, and long-term nitrate therapy. It works by dilating venous and arterial blood vessels, reducing preload and afterload, and improving coronary blood flow. NITROOT-2.6 is particularly beneficial for patients initiating long-acting nitrate therapy, those requiring lower-dose nitrate prophylaxis, elderly patients, and individuals requiring sustained symptom control with improved myocardial perfusion. Technical Knowledge of Nitroglycerin Controlled Release Nitroglycerin is converted within vascular smooth muscle cells to nitric oxide (NO), which activates guanylate cyclase and increases cyclic guanosine monophosphate (cGMP) levels. Elevated cGMP causes relaxation of vascular smooth muscle, resulting in venous and arterial vasodilation. The controlled-release formulation allows gradual release of nitroglycerin over an extended period, providing sustained anti-anginal activity while reducing fluctuations in plasma concentration. Mechanism of Action Nitroglycerin releases nitric oxide, increases cGMP levels, relaxes vascular smooth muscle, produces venous and arterial vasodilation, reduces preload and afterload, decreases myocardial oxygen demand, and improves coronary blood flow. Key Benefits Helps prevent chronic angina attacks Provides sustained anti-anginal protection Reduces myocardial oxygen demand Improves coronary blood flow Enhances exercise tolerance Reduces frequency of nitrate use for breakthrough angina Supports long-term ischemic heart disease management Suitable for chronic anti-anginal therapy under medical supervision Clinical Applications NITROOT-2.6 is commonly prescribed for chronic stable angina pectoris, coronary artery disease, ischemic heart disease, post-myocardial infarction angina prevention, long-term nitrate therapy, prevention of recurrent angina episodes, and patients requiring lower-dose nitrate prophylaxis. Facts About Nitroglycerin Nitroglycerin is one of the oldest and most extensively studied anti-anginal medications in cardiovascular medicine. Controlled-release nitrate formulations provide prolonged symptom prevention and improved patient compliance in chronic angina management. The 2.6 mg strength is particularly useful for therapy initiation, dose adjustment, elderly patients, and patients requiring individualized long-acting nitrate therapy. Appropriate dosing schedules are important to minimize nitrate tolerance during long-term therapy. Key Facts Long-acting nitrate anti-anginal therapy Nitroglycerin Controlled Release 2.6 mg for sustained angina prevention Provides prolonged coronary vasodilation Reduces myocardial oxygen demand Improves exercise tolerance in chronic angina Evidence-based cardiovascular therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity NITROOT-2.6 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of coronary artery disease, chronic angina, diabetes, hypertension, and ischemic heart disease creates strong prescription demand and long-term market potential for this formulation. Why Choose NITROOT-2.6 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Nitroglycerin Controlled Release 2.6 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented controlled-release formulation Controlled-release tablet manufacturing technology Blister and Alu-Alu packaging options NITROOT-2.6 from DIABGLYM combines sustained anti-anginal protection, improved coronary perfusion, evidence-based cardiovascular therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Nitroglycerin controlled-release formulation.

NITROOT-4.6 Nitroglycerin Controlled Release 6.4 mg Tablets Division: DIABGLYM Composition Each controlled-release tablet contains: Nitroglycerin IP — 6.4 mg Excipients — q.s. Colour: Approved colour used Dosage form: Controlled-release oral tablet Product Description NITROOT-4.6 contains Nitroglycerin Controlled Release 6.4 mg, a long-acting nitrate formulation designed for the prevention and long-term management of chronic stable angina pectoris and ischemic heart disease. The controlled-release formulation provides sustained release of nitroglycerin, helping reduce the frequency of angina attacks, improve exercise tolerance, and decrease myocardial oxygen demand. Nitroglycerin is a well-established anti-anginal agent widely used in cardiology for patients with chronic coronary artery disease, recurrent angina, post-myocardial infarction ischemia, and long-term nitrate therapy. It works by dilating venous and arterial blood vessels, reducing preload and afterload, and improving coronary blood flow. NITROOT-4.6 is particularly beneficial for patients requiring long-duration anti-anginal prophylaxis, sustained symptom control, improved myocardial perfusion, and enhanced quality of life. Technical Knowledge of Nitroglycerin Controlled Release Nitroglycerin is converted within vascular smooth muscle cells to nitric oxide (NO), which activates guanylate cyclase and increases cyclic guanosine monophosphate (cGMP) levels. Elevated cGMP causes relaxation of vascular smooth muscle, resulting in venous and arterial vasodilation. The controlled-release formulation allows gradual release of nitroglycerin over an extended period, providing sustained anti-anginal activity while reducing fluctuations in plasma concentration. Mechanism of Action Nitroglycerin releases nitric oxide, increases cGMP levels, relaxes vascular smooth muscle, produces venous and arterial vasodilation, reduces preload and afterload, decreases myocardial oxygen demand, and improves coronary blood flow. Key Benefits Helps prevent chronic angina attacks Provides sustained anti-anginal protection Reduces myocardial oxygen demand Improves coronary blood flow Enhances exercise tolerance Reduces frequency of nitrate use for breakthrough angina Supports long-term ischemic heart disease management Suitable for chronic anti-anginal therapy under medical supervision Clinical Applications NITROOT-4.6 is commonly prescribed for chronic stable angina pectoris, coronary artery disease, ischemic heart disease, post-myocardial infarction angina prevention, long-term nitrate therapy, and prevention of recurrent angina episodes. Facts About Nitroglycerin Nitroglycerin is one of the oldest and most extensively studied anti-anginal medications in cardiovascular medicine. Controlled-release nitrate formulations provide prolonged symptom prevention and improved patient compliance in chronic angina management. Appropriate dosing schedules are important to minimize nitrate tolerance during long-term therapy. Key Facts Long-acting nitrate anti-anginal therapy Nitroglycerin Controlled Release 6.4 mg for sustained angina prevention Provides prolonged coronary vasodilation Reduces myocardial oxygen demand Improves exercise tolerance in chronic angina Evidence-based cardiovascular therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity NITROOT-4.6 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of coronary artery disease, chronic angina, diabetes, hypertension, and ischemic heart disease creates strong prescription demand and long-term market potential for this formulation. Why Choose NITROOT-4.6 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Nitroglycerin Controlled Release 6.4 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented controlled-release formulation Controlled-release tablet manufacturing technology Blister and Alu-Alu packaging options NITROOT-4.6 from DIABGLYM combines sustained anti-anginal protection, improved coronary perfusion, evidence-based cardiovascular therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Nitroglycerin controlled-release formulation.

OLMEROOT-AM 40/5 Olmesartan Medoxomil 40 mg and Amlodipine 5 mg Tablets Division: DIABGLYM Composition Each tablet contains: Olmesartan Medoxomil IP — 40 mg Amlodipine IP — 5 mg Excipients — q.s. Colour: Approved colour used Dosage form: Oral tablet Product Description OLMEROOT-AM 40/5 is a scientifically balanced antihypertensive combination of Olmesartan Medoxomil 40 mg and Amlodipine 5 mg, formulated for the effective management of moderate to severe hypertension and long-term cardiovascular risk reduction. This combination provides dual blood pressure control by combining the renin-angiotensin system blockade of Olmesartan with the sustained vasodilatory action of Amlodipine, resulting in superior antihypertensive efficacy and enhanced target organ protection. Olmesartan Medoxomil is a potent angiotensin II receptor blocker (ARB) that promotes vasodilation, reduces peripheral vascular resistance, and provides cardiovascular and renal protection. Amlodipine is a long-acting calcium channel blocker that relaxes vascular smooth muscle, improves arterial compliance, and provides sustained 24-hour blood pressure control. OLMEROOT-AM 40/5 is particularly beneficial in patients with uncontrolled hypertension, hypertension associated with diabetes, chronic kidney disease, metabolic syndrome, obesity, elderly hypertension, left ventricular hypertrophy, and patients requiring intensive combination antihypertensive therapy. Technical Knowledge of Olmesartan Medoxomil and Amlodipine Olmesartan Medoxomil is a prodrug that is converted to Olmesartan, which selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction, aldosterone secretion, sympathetic activation, and vascular remodeling. Amlodipine inhibits L-type calcium channels in vascular smooth muscle, producing sustained arterial vasodilation, reducing peripheral vascular resistance, improving vascular compliance, and maintaining stable blood pressure control throughout the dosing interval. The combination of Olmesartan and Amlodipine provides complementary antihypertensive mechanisms with enhanced cardiovascular and renal protective benefits. Mechanism of Action Olmesartan blocks AT1 receptors, promotes vasodilation, reduces peripheral vascular resistance, decreases aldosterone secretion, improves vascular function, and protects cardiovascular and renal tissues. Amlodipine relaxes vascular smooth muscle, reduces arterial resistance, improves vascular compliance, enhances coronary blood flow, and provides sustained antihypertensive action. Key Benefits Effective reduction of systolic and diastolic blood pressure Dual antihypertensive mechanism Provides sustained 24-hour blood pressure control Supports cardiovascular and renal protection Improves vascular compliance and endothelial function Reduces peripheral vascular resistance Effective in diabetic and chronic kidney disease patients Convenient once-daily dosing Suitable for long-term hypertension management under medical supervision Clinical Applications OLMEROOT-AM 40/5 is commonly prescribed for moderate to severe hypertension, uncontrolled hypertension requiring combination therapy, hypertension with diabetes mellitus, hypertension with chronic kidney disease, hypertension with metabolic syndrome, elderly hypertension, left ventricular hypertrophy, and long-term cardiovascular risk reduction. Facts About Olmesartan Medoxomil and Amlodipine Olmesartan is a highly selective ARB with excellent antihypertensive efficacy and proven cardiovascular and renal protective benefits. Amlodipine is one of the most extensively prescribed calcium channel blockers worldwide and provides effective long-term blood pressure control. The combination is widely recommended for patients requiring dual antihypertensive therapy because of its excellent efficacy, tolerability, and target organ protective effects. Key Facts ARB and calcium channel blocker combination therapy Olmesartan Medoxomil 40 mg for intensive vascular and renal protection Amlodipine 5 mg for sustained arterial vasodilation Provides 24-hour comprehensive blood pressure control Effective in moderate to severe hypertension Evidence-based cardiovascular combination therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity OLMEROOT-AM 40/5 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, chronic kidney disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination. Why Choose OLMEROOT-AM 40/5 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Olmesartan Medoxomil 40 mg and Amlodipine 5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented formulation Moisture-controlled tablet manufacturing Blister and Alu-Alu packaging options OLMEROOT-AM 40/5 from DIABGLYM combines effective blood pressure control, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Olmesartan and Amlodipine formulation.

OLMEROOT-A Olmesartan Medoxomil and Amlodipine Tablets Division: DIABGLYM Composition Each tablet contains: Olmesartan Medoxomil IP — 20 mg Amlodipine IP — 5 mg Excipients — q.s. Colour: Approved colour used Dosage form: Oral tablet Product Description OLMEROOT-A is a scientifically balanced antihypertensive combination of Olmesartan Medoxomil and Amlodipine, formulated for the effective management of hypertension and long-term cardiovascular risk reduction. This combination provides dual blood pressure control by combining the renin-angiotensin system blockade of Olmesartan with the sustained vasodilatory action of Amlodipine, resulting in superior antihypertensive efficacy and enhanced target organ protection. Olmesartan Medoxomil is a potent angiotensin II receptor blocker (ARB) that promotes vasodilation, reduces peripheral vascular resistance, and provides cardiovascular and renal protection. Amlodipine is a long-acting calcium channel blocker that relaxes vascular smooth muscle, improves arterial compliance, and provides sustained 24-hour blood pressure control. OLMEROOT-A is particularly beneficial in patients with uncontrolled hypertension, hypertension associated with diabetes, chronic kidney disease, metabolic syndrome, obesity, elderly hypertension, left ventricular hypertrophy, and patients requiring combination antihypertensive therapy. Technical Knowledge of Olmesartan Medoxomil and Amlodipine Olmesartan Medoxomil is a prodrug that is converted to Olmesartan, which selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction, aldosterone secretion, sympathetic activation, and vascular remodeling. Amlodipine inhibits L-type calcium channels in vascular smooth muscle, producing sustained arterial vasodilation, reducing peripheral vascular resistance, improving vascular compliance, and maintaining stable blood pressure control throughout the dosing interval. The combination of Olmesartan and Amlodipine provides complementary antihypertensive mechanisms with enhanced cardiovascular and renal protective benefits. Mechanism of Action Olmesartan blocks AT1 receptors, promotes vasodilation, reduces peripheral vascular resistance, decreases aldosterone secretion, improves vascular function, and protects cardiovascular and renal tissues. Amlodipine relaxes vascular smooth muscle, reduces arterial resistance, improves vascular compliance, enhances coronary blood flow, and provides sustained antihypertensive action. Key Benefits Effective reduction of systolic and diastolic blood pressure Dual antihypertensive mechanism Provides sustained 24-hour blood pressure control Supports cardiovascular and renal protection Improves vascular compliance and endothelial function Reduces peripheral vascular resistance Effective in diabetic and chronic kidney disease patients Convenient once-daily dosing Suitable for long-term hypertension management under medical supervision Clinical Applications OLMEROOT-A is commonly prescribed for essential hypertension, uncontrolled hypertension requiring combination therapy, hypertension with diabetes mellitus, hypertension with chronic kidney disease, hypertension with metabolic syndrome, elderly hypertension, left ventricular hypertrophy, and long-term cardiovascular risk reduction. Facts About Olmesartan Medoxomil and Amlodipine Olmesartan is a highly selective ARB with excellent antihypertensive efficacy and proven cardiovascular and renal protective benefits. Amlodipine is one of the most extensively prescribed calcium channel blockers worldwide and provides effective long-term blood pressure control. The combination is widely recommended for patients requiring dual antihypertensive therapy because of its excellent efficacy, tolerability, and target organ protective effects. Key Facts ARB and calcium channel blocker combination therapy Olmesartan Medoxomil for vascular and renal protection Amlodipine for sustained arterial vasodilation Provides 24-hour comprehensive blood pressure control Effective in hypertension with diabetes and chronic kidney disease Evidence-based cardiovascular combination therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity OLMEROOT-A is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, chronic kidney disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination. Why Choose OLMEROOT-A for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Olmesartan Medoxomil and Amlodipine Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented formulation Moisture-controlled tablet manufacturing Blister and Alu-Alu packaging options OLMEROOT-A from DIABGLYM combines effective blood pressure control, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Olmesartan and Amlodipine formulation.

OLMEROOT-ACH Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tablets Division: DIABGLYM Composition Each tablet contains: Olmesartan Medoxomil IP — 20 mg Amlodipine IP — 5 mg Hydrochlorothiazide IP — 12.5 mg Excipients — q.s. Colour: Approved colour used Dosage form: Oral tablet Product Description OLMEROOT-ACH is an advanced triple-combination antihypertensive formulation containing Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide, designed for the effective management of moderate to severe hypertension and long-term cardiovascular risk reduction. This combination targets three complementary mechanisms involved in blood pressure regulation, providing superior blood pressure control and enhanced cardiovascular and renal protection. Olmesartan Medoxomil is a potent angiotensin II receptor blocker (ARB) that promotes vasodilation and protects cardiovascular and renal function. Amlodipine is a long-acting calcium channel blocker that relaxes vascular smooth muscle and reduces peripheral vascular resistance. Hydrochlorothiazide is a thiazide diuretic that enhances sodium and water excretion while contributing to effective blood pressure reduction. OLMEROOT-ACH is particularly beneficial for patients with uncontrolled hypertension, resistant hypertension, hypertension associated with diabetes, chronic kidney disease, obesity, metabolic syndrome, left ventricular hypertrophy, and patients requiring intensive combination antihypertensive therapy. Technical Knowledge of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Olmesartan Medoxomil is converted to Olmesartan, which selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction, aldosterone secretion, and vascular remodeling. Amlodipine inhibits L-type calcium channels in vascular smooth muscle, producing sustained arterial vasodilation and reduction of peripheral vascular resistance. Hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary sodium and water excretion, reducing plasma volume, and contributing to long-term blood pressure reduction. The combination of Olmesartan, Amlodipine, and Hydrochlorothiazide provides complementary antihypertensive mechanisms with superior efficacy compared with dual therapy and improved cardiovascular and renal protection. Mechanism of Action Olmesartan blocks AT1 receptors, promotes vasodilation, reduces peripheral vascular resistance, decreases aldosterone secretion, and protects cardiovascular and renal tissues. Amlodipine relaxes vascular smooth muscle, reduces arterial resistance, improves vascular compliance, and provides sustained antihypertensive action. Hydrochlorothiazide promotes sodium and water excretion, reduces plasma volume, decreases peripheral vascular resistance, and enhances overall antihypertensive efficacy. Key Benefits Powerful triple antihypertensive mechanism Superior reduction of systolic and diastolic blood pressure Provides sustained 24-hour blood pressure control Supports cardiovascular and renal protection Reduces peripheral vascular resistance Improves vascular compliance Effective diuretic support Effective in resistant and uncontrolled hypertension Suitable for long-term hypertension management under medical supervision Clinical Applications OLMEROOT-ACH is commonly prescribed for moderate to severe hypertension, resistant hypertension, uncontrolled hypertension requiring triple therapy, hypertension with diabetes mellitus, hypertension with chronic kidney disease, hypertension with obesity, metabolic syndrome, left ventricular hypertrophy, and long-term cardiovascular risk reduction. Facts About Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Triple-combination antihypertensive therapy is widely recommended for patients with uncontrolled hypertension requiring intensive blood pressure management. Olmesartan provides RAAS blockade and organ protection, Amlodipine provides sustained vasodilation, and Hydrochlorothiazide provides effective diuretic support. This combination offers comprehensive blood pressure control with strong evidence for reduction of cardiovascular events and target organ damage. Key Facts Advanced triple antihypertensive combination therapy Olmesartan Medoxomil for vascular and renal protection Amlodipine for sustained arterial vasodilation Hydrochlorothiazide for effective diuretic support Provides 24-hour comprehensive blood pressure control Effective in resistant hypertension and high-risk cardiovascular patients Evidence-based cardiovascular combination therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity OLMEROOT-ACH is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of resistant hypertension, diabetes, chronic kidney disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this advanced combination. Why Choose OLMEROOT-ACH for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented formulation Moisture-controlled tablet manufacturing Blister and Alu-Alu packaging options OLMEROOT-ACH from DIABGLYM combines powerful triple blood pressure control, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Olmesartan, Amlodipine, and Hydrochlorothiazide formulation.

OLMEROOT-ACH Olmesartan Medoxomil, Amlodipine and Chlorthalidone Tablets Division: DIABGLYM Composition Each tablet contains: Olmesartan Medoxomil IP — 20 mg Amlodipine IP — 5 mg Chlorthalidone IP — 12.5 mg Excipients — q.s. Colour: Approved colour used Dosage form: Oral tablet Product Description OLMEROOT-ACH is an advanced triple-combination antihypertensive formulation containing Olmesartan Medoxomil, Amlodipine, and Chlorthalidone, designed for the effective management of moderate to severe hypertension and long-term cardiovascular risk reduction. This combination targets three complementary mechanisms involved in blood pressure regulation, providing superior blood pressure control and enhanced cardiovascular and renal protection. Olmesartan Medoxomil is a potent angiotensin II receptor blocker (ARB) that promotes vasodilation and protects cardiovascular and renal function. Amlodipine is a long-acting calcium channel blocker that relaxes vascular smooth muscle and reduces peripheral vascular resistance. Chlorthalidone is a long-acting thiazide-like diuretic that enhances sodium and water excretion while providing sustained antihypertensive efficacy. OLMEROOT-ACH is particularly beneficial for patients with uncontrolled hypertension, resistant hypertension, hypertension associated with diabetes, chronic kidney disease, obesity, metabolic syndrome, left ventricular hypertrophy, and patients requiring intensive combination antihypertensive therapy. Technical Knowledge of Olmesartan Medoxomil, Amlodipine and Chlorthalidone Olmesartan Medoxomil is converted to Olmesartan, which selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction, aldosterone secretion, and vascular remodeling. Amlodipine inhibits L-type calcium channels in vascular smooth muscle, producing sustained arterial vasodilation and reduction of peripheral vascular resistance. Chlorthalidone inhibits sodium and chloride reabsorption in the distal convoluted tubule and has a prolonged half-life that provides extended blood pressure control throughout the day. The combination of Olmesartan, Amlodipine, and Chlorthalidone provides complementary antihypertensive mechanisms with superior efficacy compared with dual therapy and improved cardiovascular and renal protection. Mechanism of Action Olmesartan blocks AT1 receptors, promotes vasodilation, reduces peripheral vascular resistance, decreases aldosterone secretion, and protects cardiovascular and renal tissues. Amlodipine relaxes vascular smooth muscle, reduces arterial resistance, improves vascular compliance, and provides sustained antihypertensive action. Chlorthalidone promotes sodium and water excretion, reduces plasma volume, decreases peripheral vascular resistance, and enhances overall antihypertensive efficacy. Key Benefits Powerful triple antihypertensive mechanism Superior reduction of systolic and diastolic blood pressure Provides sustained 24-hour blood pressure control Supports cardiovascular and renal protection Reduces peripheral vascular resistance Improves vascular compliance Long-acting diuretic support Effective in resistant and uncontrolled hypertension Suitable for long-term hypertension management under medical supervision Clinical Applications OLMEROOT-ACH is commonly prescribed for moderate to severe hypertension, resistant hypertension, uncontrolled hypertension requiring triple therapy, hypertension with diabetes mellitus, hypertension with chronic kidney disease, hypertension with obesity, metabolic syndrome, left ventricular hypertrophy, and long-term cardiovascular risk reduction. Facts About Olmesartan Medoxomil, Amlodipine and Chlorthalidone Triple-combination antihypertensive therapy is widely recommended for patients with uncontrolled hypertension requiring intensive blood pressure management. Olmesartan provides RAAS blockade and organ protection, Amlodipine provides sustained vasodilation, and Chlorthalidone provides prolonged diuretic efficacy. This combination offers comprehensive blood pressure control with strong evidence for reduction of cardiovascular events and target organ damage. Key Facts Advanced triple antihypertensive combination therapy Olmesartan Medoxomil for vascular and renal protection Amlodipine for sustained arterial vasodilation Chlorthalidone for long-acting diuretic support Provides 24-hour comprehensive blood pressure control Effective in resistant hypertension and high-risk cardiovascular patients Evidence-based cardiovascular combination therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity OLMEROOT-ACH is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of resistant hypertension, diabetes, chronic kidney disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this advanced combination. Why Choose OLMEROOT-ACH for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Olmesartan Medoxomil, Amlodipine, and Chlorthalidone Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented formulation Moisture-controlled tablet manufacturing Blister and Alu-Alu packaging options OLMEROOT-ACH from DIABGLYM combines powerful triple blood pressure control, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Olmesartan, Amlodipine, and Chlorthalidone formulation.

OLMEROOT-CH Olmesartan Medoxomil 20 mg and Chlorthalidone 12.5 mg Tablets Division: DIABGLYM Composition Each tablet contains: Olmesartan Medoxomil IP — 20 mg Chlorthalidone IP — 12.5 mg Excipients — q.s. Colour: Approved colour used Dosage form: Oral tablet Product Description OLMEROOT-CH is a scientifically balanced antihypertensive combination of Olmesartan Medoxomil 20 mg and Chlorthalidone 12.5 mg, formulated for the effective management of hypertension and long-term cardiovascular risk reduction. This combination provides dual blood pressure control by combining the renin-angiotensin system blockade of Olmesartan with the long-acting diuretic action of Chlorthalidone, resulting in superior antihypertensive efficacy and enhanced target organ protection. Olmesartan Medoxomil is a potent angiotensin II receptor blocker (ARB) that promotes vasodilation, reduces peripheral vascular resistance, and provides cardiovascular and renal protection. Chlorthalidone is a long-acting thiazide-like diuretic that increases sodium and water excretion, reduces plasma volume, decreases peripheral vascular resistance, and provides sustained blood pressure control over 24 hours. OLMEROOT-CH is particularly beneficial in patients with uncontrolled hypertension, hypertension associated with diabetes, chronic kidney disease, obesity, metabolic syndrome, elderly hypertension, and patients requiring intensive combination antihypertensive therapy. Technical Knowledge of Olmesartan Medoxomil and Chlorthalidone Olmesartan Medoxomil is a prodrug that is converted to Olmesartan, which selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction, aldosterone secretion, sympathetic activation, and vascular remodeling. Chlorthalidone acts primarily on the distal convoluted tubule of the nephron by inhibiting sodium and chloride reabsorption. Compared with Hydrochlorothiazide, Chlorthalidone has a longer half-life and prolonged antihypertensive activity, providing more sustained blood pressure control and improved cardiovascular protection. The combination of Olmesartan and Chlorthalidone provides complementary antihypertensive mechanisms with additional cardiovascular and renal protective benefits. Mechanism of Action Olmesartan blocks AT1 receptors, promotes vasodilation, reduces peripheral vascular resistance, decreases aldosterone secretion, improves vascular function, and protects cardiovascular and renal tissues. Chlorthalidone promotes sodium and water excretion, reduces plasma volume, decreases peripheral vascular resistance, provides prolonged diuretic activity, and enhances antihypertensive efficacy. Key Benefits Effective reduction of systolic and diastolic blood pressure Dual antihypertensive mechanism Provides sustained 24-hour blood pressure control Supports cardiovascular and renal protection Reduces peripheral vascular resistance Long-acting diuretic support Improves blood pressure control compared with monotherapy Suitable for long-term hypertension management under medical supervision Clinical Applications OLMEROOT-CH is commonly prescribed for essential hypertension, uncontrolled hypertension requiring combination therapy, hypertension with diabetes mellitus, hypertension with chronic kidney disease, hypertension with obesity, metabolic syndrome, elderly hypertension, and long-term cardiovascular risk reduction. Facts About Olmesartan Medoxomil and Chlorthalidone Olmesartan is a highly selective ARB with excellent antihypertensive efficacy and proven cardiovascular and renal protective benefits. Chlorthalidone is a long-acting thiazide-like diuretic with extensive clinical evidence demonstrating superior duration of action and significant reduction in cardiovascular events. The combination is widely used for patients requiring intensive blood pressure control and sustained antihypertensive therapy. Key Facts ARB and long-acting thiazide-like diuretic combination therapy Olmesartan Medoxomil 20 mg for vascular and renal protection Chlorthalidone 12.5 mg for prolonged antihypertensive control Provides sustained 24-hour blood pressure reduction Effective in hypertension requiring combination therapy Evidence-based cardiovascular combination therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity OLMEROOT-CH is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, chronic kidney disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination. Why Choose OLMEROOT-CH for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Olmesartan Medoxomil 20 mg and Chlorthalidone 12.5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented formulation Moisture-controlled tablet manufacturing Blister and Alu-Alu packaging options OLMEROOT-CH from DIABGLYM combines effective blood pressure control, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Olmesartan and Chlorthalidone formulation.

OLMEROOT-CL 20 Olmesartan Medoxomil 20 mg and Cilnidipine 10 mg Tablets Division: DIABGLYM Composition Each tablet contains: Olmesartan Medoxomil IP — 20 mg Cilnidipine IP — 10 mg Excipients — q.s. Colour: Approved colour used Dosage form: Oral tablet Product Description OLMEROOT-CL 20 is a scientifically balanced antihypertensive combination of Olmesartan Medoxomil 20 mg and Cilnidipine 10 mg, formulated for the effective management of hypertension and long-term cardiovascular and renal protection. This combination provides dual blood pressure control by combining the renin-angiotensin system blockade of Olmesartan with the advanced dual calcium channel blocking action of Cilnidipine, resulting in superior antihypertensive efficacy and enhanced target organ protection. Olmesartan Medoxomil is a potent angiotensin II receptor blocker (ARB) that promotes vasodilation, reduces peripheral vascular resistance, and provides cardiovascular and renal protection. Cilnidipine is a unique dual L-type and N-type calcium channel blocker that reduces peripheral vascular resistance, suppresses sympathetic overactivity, improves renal hemodynamics, and minimizes reflex tachycardia. OLMEROOT-CL 20 is particularly beneficial in patients with uncontrolled hypertension, hypertension associated with diabetes, chronic kidney disease, proteinuria, metabolic syndrome, elderly hypertension, and patients requiring combination antihypertensive therapy. Technical Knowledge of Olmesartan Medoxomil and Cilnidipine Olmesartan Medoxomil is a prodrug that is converted to Olmesartan, which selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction, aldosterone secretion, sympathetic activation, and vascular remodeling. Cilnidipine blocks both L-type calcium channels in vascular smooth muscle and N-type calcium channels in sympathetic nerve terminals. This dual mechanism reduces arterial vasoconstriction while decreasing sympathetic neurotransmitter release, resulting in sustained blood pressure reduction, improved renal perfusion, and reduced glomerular hypertension. The combination of Olmesartan and Cilnidipine provides complementary antihypertensive mechanisms with additional cardiovascular and nephroprotective benefits. Mechanism of Action Olmesartan blocks AT1 receptors, promotes vasodilation, reduces peripheral vascular resistance, decreases aldosterone secretion, improves vascular function, and protects cardiovascular and renal tissues. Cilnidipine blocks L-type and N-type calcium channels, relaxes vascular smooth muscle, suppresses sympathetic activity, improves renal blood flow, reduces glomerular pressure, and provides sustained antihypertensive action. Key Benefits Effective reduction of systolic and diastolic blood pressure Dual antihypertensive mechanism Provides sustained 24-hour blood pressure control Supports cardiovascular and renal protection Reduces sympathetic overactivity Improves renal hemodynamics Helps reduce proteinuria in diabetic and renal patients Minimizes reflex tachycardia Suitable for long-term hypertension management under medical supervision Clinical Applications OLMEROOT-CL 20 is commonly prescribed for essential hypertension, uncontrolled hypertension requiring combination therapy, hypertension with diabetes mellitus, hypertension with chronic kidney disease, hypertension with proteinuria, metabolic syndrome, elderly hypertension, and long-term cardiovascular and renal risk reduction. Facts About Olmesartan Medoxomil and Cilnidipine Olmesartan is a highly selective ARB with excellent antihypertensive efficacy and proven cardiovascular and renal protective benefits. Cilnidipine is an advanced calcium channel blocker with dual L-type and N-type channel blocking properties, providing effective blood pressure control with favorable renal and sympathetic modulation effects. The combination is widely used for patients requiring intensive blood pressure control and enhanced nephroprotection. Key Facts ARB and dual calcium channel blocker combination therapy Olmesartan Medoxomil 20 mg for vascular and renal protection Cilnidipine 10 mg for advanced blood pressure and renal control Provides sustained 24-hour antihypertensive action Effective in hypertension with diabetes and chronic kidney disease Evidence-based cardiovascular and nephroprotective combination therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity OLMEROOT-CL 20 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, Nephrology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, chronic kidney disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination. Why Choose OLMEROOT-CL 20 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Olmesartan Medoxomil 20 mg and Cilnidipine 10 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented formulation Moisture-controlled tablet manufacturing Blister and Alu-Alu packaging options OLMEROOT-CL 20 from DIABGLYM combines effective blood pressure control, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Olmesartan and Cilnidipine formulation.

OLMEROOT-CL 40 Olmesartan Medoxomil 40 mg and Cilnidipine 10 mg Tablets Division: DIABGLYM Composition Each tablet contains: Olmesartan Medoxomil IP — 40 mg Cilnidipine IP — 10 mg Excipients — q.s. Colour: Approved colour used Dosage form: Oral tablet Product Description OLMEROOT-CL 40 is a scientifically balanced antihypertensive combination of Olmesartan Medoxomil 40 mg and Cilnidipine 10 mg, formulated for the effective management of hypertension and long-term cardiovascular and renal protection. This combination provides dual blood pressure control by combining the renin-angiotensin system blockade of Olmesartan with the advanced dual calcium channel blocking action of Cilnidipine, resulting in superior antihypertensive efficacy and enhanced target organ protection. Olmesartan Medoxomil is a potent angiotensin II receptor blocker (ARB) that promotes vasodilation, reduces peripheral vascular resistance, and provides cardiovascular and renal protection. Cilnidipine is a unique dual L-type and N-type calcium channel blocker that reduces peripheral vascular resistance, suppresses sympathetic overactivity, improves renal hemodynamics, and minimizes reflex tachycardia. OLMEROOT-CL 40 is particularly beneficial in patients with uncontrolled hypertension, hypertension associated with diabetes, chronic kidney disease, proteinuria, metabolic syndrome, elderly hypertension, and patients requiring intensive combination antihypertensive therapy. Technical Knowledge of Olmesartan Medoxomil and Cilnidipine Olmesartan Medoxomil is a prodrug that is converted to Olmesartan, which selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction, aldosterone secretion, sympathetic activation, and vascular remodeling. Cilnidipine blocks both L-type calcium channels in vascular smooth muscle and N-type calcium channels in sympathetic nerve terminals. This dual mechanism reduces arterial vasoconstriction while decreasing sympathetic neurotransmitter release, resulting in sustained blood pressure reduction, improved renal perfusion, and reduced glomerular hypertension. The combination of Olmesartan and Cilnidipine provides complementary antihypertensive mechanisms with additional cardiovascular and nephroprotective benefits. Mechanism of Action Olmesartan blocks AT1 receptors, promotes vasodilation, reduces peripheral vascular resistance, decreases aldosterone secretion, improves vascular function, and protects cardiovascular and renal tissues. Cilnidipine blocks L-type and N-type calcium channels, relaxes vascular smooth muscle, suppresses sympathetic activity, improves renal blood flow, reduces glomerular pressure, and provides sustained antihypertensive action. Key Benefits Effective reduction of systolic and diastolic blood pressure Dual antihypertensive mechanism Provides sustained 24-hour blood pressure control Supports cardiovascular and renal protection Reduces sympathetic overactivity Improves renal hemodynamics Helps reduce proteinuria in diabetic and renal patients Minimizes reflex tachycardia Suitable for long-term hypertension management under medical supervision Clinical Applications OLMEROOT-CL 40 is commonly prescribed for essential hypertension, uncontrolled hypertension requiring combination therapy, hypertension with diabetes mellitus, hypertension with chronic kidney disease, hypertension with proteinuria, metabolic syndrome, elderly hypertension, and long-term cardiovascular and renal risk reduction. Facts About Olmesartan Medoxomil and Cilnidipine Olmesartan is a highly selective ARB with excellent antihypertensive efficacy and proven cardiovascular and renal protective benefits. Cilnidipine is an advanced calcium channel blocker with dual L-type and N-type channel blocking properties, providing effective blood pressure control with favorable renal and sympathetic modulation effects. The combination is widely used for patients requiring intensive blood pressure control and enhanced nephroprotection. Key Facts ARB and dual calcium channel blocker combination therapy Olmesartan Medoxomil 40 mg for vascular and renal protection Cilnidipine 10 mg for advanced blood pressure and renal control Provides sustained 24-hour antihypertensive action Effective in hypertension with diabetes and chronic kidney disease Evidence-based cardiovascular and nephroprotective combination therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity OLMEROOT-CL 40 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, Nephrology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, chronic kidney disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination. Why Choose OLMEROOT-CL 40 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Olmesartan Medoxomil 40 mg and Cilnidipine 10 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented formulation Moisture-controlled tablet manufacturing Blister and Alu-Alu packaging options OLMEROOT-CL 40 from DIABGLYM combines effective blood pressure control, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Olmesartan and Cilnidipine formulation.

OLMEROOT-H Olmesartan Medoxomil 20 mg and Hydrochlorothiazide 12.5 mg Tablets Division: DIABGLYM Composition Each tablet contains: Olmesartan Medoxomil IP — 20 mg Hydrochlorothiazide IP — 12.5 mg Excipients — q.s. Colour: Approved colour used Dosage form: Oral tablet Product Description OLMEROOT-H is a scientifically balanced antihypertensive combination of Olmesartan Medoxomil 20 mg and Hydrochlorothiazide 12.5 mg, formulated for the effective management of hypertension and long-term cardiovascular risk reduction. This combination provides dual blood pressure control by combining the renin-angiotensin system blockade of Olmesartan with the diuretic action of Hydrochlorothiazide, resulting in superior antihypertensive efficacy and enhanced target organ protection. Olmesartan Medoxomil is a potent angiotensin II receptor blocker (ARB) that promotes vasodilation, reduces peripheral vascular resistance, and provides cardiovascular and renal protection. Hydrochlorothiazide is a thiazide diuretic that increases sodium and water excretion, reduces plasma volume, decreases peripheral vascular resistance, and enhances the antihypertensive effect of Olmesartan. OLMEROOT-H is particularly beneficial in patients with uncontrolled hypertension, hypertension associated with diabetes, chronic kidney disease, obesity, metabolic syndrome, elderly hypertension, and patients requiring combination antihypertensive therapy. Technical Knowledge of Olmesartan Medoxomil and Hydrochlorothiazide Olmesartan Medoxomil is a prodrug that is converted to Olmesartan, which selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction, aldosterone secretion, sympathetic activation, and vascular remodeling. Hydrochlorothiazide acts on the distal convoluted tubule of the nephron by inhibiting sodium-chloride reabsorption, resulting in increased urinary excretion of sodium, chloride, and water. Long-term therapy reduces peripheral vascular resistance and contributes to sustained blood pressure reduction. The combination of Olmesartan and Hydrochlorothiazide provides complementary antihypertensive mechanisms with additional cardiovascular and renal protective benefits. Mechanism of Action Olmesartan blocks AT1 receptors, promotes vasodilation, reduces peripheral vascular resistance, decreases aldosterone secretion, improves vascular function, and protects cardiovascular and renal tissues. Hydrochlorothiazide promotes sodium and water excretion, reduces plasma volume, decreases peripheral vascular resistance, and enhances antihypertensive efficacy. Key Benefits Effective reduction of systolic and diastolic blood pressure Dual antihypertensive mechanism Provides sustained 24-hour blood pressure control Supports cardiovascular and renal protection Reduces peripheral vascular resistance Helps control fluid-related hypertension Improves overall blood pressure control compared with monotherapy Suitable for long-term hypertension management under medical supervision Clinical Applications OLMEROOT-H is commonly prescribed for essential hypertension, uncontrolled hypertension requiring combination therapy, hypertension with diabetes mellitus, hypertension with chronic kidney disease, hypertension with obesity, metabolic syndrome, elderly hypertension, and long-term cardiovascular risk reduction. Facts About Olmesartan Medoxomil and Hydrochlorothiazide Olmesartan is a highly selective ARB with excellent antihypertensive efficacy and proven cardiovascular and renal protective benefits. Hydrochlorothiazide is a well-established thiazide diuretic that has been extensively studied in hypertension management and cardiovascular outcome trials. The combination is widely recommended for patients requiring dual antihypertensive therapy and improved blood pressure control. Key Facts ARB and thiazide diuretic combination therapy Olmesartan Medoxomil 20 mg for vascular and renal protection Hydrochlorothiazide 12.5 mg for effective diuretic support Provides sustained 24-hour antihypertensive action Effective in hypertension requiring combination therapy Evidence-based cardiovascular combination therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity OLMEROOT-H is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, chronic kidney disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination. Why Choose OLMEROOT-H for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Olmesartan Medoxomil 20 mg and Hydrochlorothiazide 12.5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented formulation Moisture-controlled tablet manufacturing Blister and Alu-Alu packaging options OLMEROOT-H from DIABGLYM combines effective blood pressure control, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Olmesartan and Hydrochlorothiazide formulation.

OLMEROOT-MT 25 Olmesartan Medoxomil 20 mg and Metoprolol Succinate Extended Release 25 mg Tablets Division: DIABGLYM Composition Each extended-release tablet contains: Olmesartan Medoxomil IP — 20 mg Metoprolol Succinate Extended Release IP equivalent to Metoprolol — 25 mg Excipients — q.s. Colour: Approved colour used Dosage form: Extended-release oral tablet Product Description OLMEROOT-MT 25 is a scientifically balanced antihypertensive combination of Olmesartan Medoxomil 20 mg and Metoprolol Succinate Extended Release 25 mg, formulated for the effective management of hypertension, coronary artery disease, and long-term cardiovascular risk reduction. This combination provides dual blood pressure control by combining the renin-angiotensin system blockade of Olmesartan with the cardioselective beta-blocking action of Metoprolol Succinate, resulting in superior blood pressure reduction and enhanced cardiovascular protection. Olmesartan Medoxomil is a potent angiotensin II receptor blocker (ARB) that promotes vasodilation, reduces peripheral vascular resistance, and provides cardiovascular and renal protection. Metoprolol Succinate Extended Release is a long-acting beta-1 selective blocker that reduces heart rate, myocardial contractility, and cardiac workload while providing sustained 24-hour cardiovascular control. OLMEROOT-MT 25 is particularly beneficial in patients with hypertension associated with tachycardia, coronary artery disease, diabetes, metabolic syndrome, left ventricular dysfunction, and high cardiovascular risk requiring combination antihypertensive therapy. Technical Knowledge of Olmesartan Medoxomil and Metoprolol Succinate Extended Release Olmesartan Medoxomil is a prodrug that is converted to Olmesartan, which selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction, aldosterone secretion, sympathetic activation, and vascular remodeling. Metoprolol Succinate Extended Release selectively blocks beta-1 adrenergic receptors in the heart, reducing sympathetic stimulation, heart rate, myocardial contractility, and renin secretion. The extended-release formulation provides stable plasma concentrations and sustained therapeutic activity throughout the day. The combination of Olmesartan and Metoprolol Succinate Extended Release provides complementary antihypertensive mechanisms with additional cardiovascular and renal protective benefits. Mechanism of Action Olmesartan blocks AT1 receptors, promotes vasodilation, reduces peripheral vascular resistance, decreases aldosterone secretion, improves vascular function, and protects cardiovascular and renal tissues. Metoprolol Succinate Extended Release reduces heart rate, decreases myocardial contractility, lowers cardiac output, suppresses renin release, and reduces myocardial oxygen demand through sustained beta-1 receptor blockade. Key Benefits Effective reduction of systolic and diastolic blood pressure Dual antihypertensive mechanism Provides sustained 24-hour blood pressure control Reduces heart rate and myocardial workload Supports cardiovascular and renal protection Improves vascular function and endothelial health Helps prevent cardiovascular events Suitable for long-term hypertension and cardiovascular management under medical supervision Clinical Applications OLMEROOT-MT 25 is commonly prescribed for essential hypertension, hypertension with tachycardia, hypertension with coronary artery disease, hypertension with diabetes mellitus, hypertension with chronic kidney disease, stable coronary artery disease, cardiovascular risk reduction, and long-term antihypertensive management. Facts About Olmesartan Medoxomil and Metoprolol Succinate Extended Release Olmesartan is a highly selective ARB with excellent antihypertensive efficacy and proven cardiovascular and renal protective benefits. Metoprolol Succinate Extended Release is a long-acting beta-blocker widely used in hypertension, ischemic heart disease, and heart failure. The combination provides comprehensive blood pressure control, heart rate reduction, and long-term cardiovascular protection with convenient once-daily dosing. Key Facts ARB and beta-blocker combination therapy Olmesartan Medoxomil 20 mg for vascular and renal protection Metoprolol Succinate Extended Release 25 mg for sustained heart rate and blood pressure control Provides 24-hour antihypertensive action Effective in hypertension and coronary artery disease Evidence-based cardiovascular combination therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity OLMEROOT-MT 25 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, coronary artery disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination. Why Choose OLMEROOT-MT 25 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Olmesartan Medoxomil 20 mg and Metoprolol Succinate Extended Release 25 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented extended-release formulation Controlled-release tablet manufacturing technology Blister and Alu-Alu packaging options OLMEROOT-MT 25 from DIABGLYM combines effective blood pressure control, sustained heart rate management, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Olmesartan and Metoprolol formulation.

OLMEROOT-MT 25 Olmesartan Medoxomil 20 mg and Metoprolol Succinate Extended Release 25 mg Tablets Division: DIABGLYM Composition Each extended-release tablet contains: Olmesartan Medoxomil IP — 20 mg Metoprolol Succinate Extended Release IP equivalent to Metoprolol — 25 mg Excipients — q.s. Colour: Approved colour used Dosage form: Extended-release oral tablet Product Description OLMEROOT-MT 25 is a scientifically balanced antihypertensive combination of Olmesartan Medoxomil 20 mg and Metoprolol Succinate Extended Release 25 mg, formulated for the effective management of hypertension, coronary artery disease, and long-term cardiovascular risk reduction. This combination provides dual blood pressure control by combining the renin-angiotensin system blockade of Olmesartan with the cardioselective beta-blocking action of Metoprolol Succinate, resulting in superior blood pressure reduction and enhanced cardiovascular protection. Olmesartan Medoxomil is a potent angiotensin II receptor blocker (ARB) that promotes vasodilation, reduces peripheral vascular resistance, and provides cardiovascular and renal protection. Metoprolol Succinate Extended Release is a long-acting beta-1 selective blocker that reduces heart rate, myocardial contractility, and cardiac workload while providing sustained 24-hour cardiovascular control. OLMEROOT-MT 25 is particularly beneficial in patients with hypertension associated with tachycardia, coronary artery disease, diabetes, metabolic syndrome, left ventricular dysfunction, and high cardiovascular risk requiring combination antihypertensive therapy. Technical Knowledge of Olmesartan Medoxomil and Metoprolol Succinate Extended Release Olmesartan Medoxomil is a prodrug that is converted to Olmesartan, which selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction, aldosterone secretion, sympathetic activation, and vascular remodeling. Metoprolol Succinate Extended Release selectively blocks beta-1 adrenergic receptors in the heart, reducing sympathetic stimulation, heart rate, myocardial contractility, and renin secretion. The extended-release formulation provides stable plasma concentrations and sustained therapeutic activity throughout the day. The combination of Olmesartan and Metoprolol Succinate Extended Release provides complementary antihypertensive mechanisms with additional cardiovascular and renal protective benefits. Mechanism of Action Olmesartan blocks AT1 receptors, promotes vasodilation, reduces peripheral vascular resistance, decreases aldosterone secretion, improves vascular function, and protects cardiovascular and renal tissues. Metoprolol Succinate Extended Release reduces heart rate, decreases myocardial contractility, lowers cardiac output, suppresses renin release, and reduces myocardial oxygen demand through sustained beta-1 receptor blockade. Key Benefits Effective reduction of systolic and diastolic blood pressure Dual antihypertensive mechanism Provides sustained 24-hour blood pressure control Reduces heart rate and myocardial workload Supports cardiovascular and renal protection Improves vascular function and endothelial health Helps prevent cardiovascular events Suitable for long-term hypertension and cardiovascular management under medical supervision Clinical Applications OLMEROOT-MT 25 is commonly prescribed for essential hypertension, hypertension with tachycardia, hypertension with coronary artery disease, hypertension with diabetes mellitus, hypertension with chronic kidney disease, stable coronary artery disease, cardiovascular risk reduction, and long-term antihypertensive management. Facts About Olmesartan Medoxomil and Metoprolol Succinate Extended Release Olmesartan is a highly selective ARB with excellent antihypertensive efficacy and proven cardiovascular and renal protective benefits. Metoprolol Succinate Extended Release is a long-acting beta-blocker widely used in hypertension, ischemic heart disease, and heart failure. The combination provides comprehensive blood pressure control, heart rate reduction, and long-term cardiovascular protection with convenient once-daily dosing. Key Facts ARB and beta-blocker combination therapy Olmesartan Medoxomil 20 mg for vascular and renal protection Metoprolol Succinate Extended Release 25 mg for sustained heart rate and blood pressure control Provides 24-hour antihypertensive action Effective in hypertension and coronary artery disease Evidence-based cardiovascular combination therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity OLMEROOT-MT 25 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, coronary artery disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination. Why Choose OLMEROOT-MT 25 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Olmesartan Medoxomil 20 mg and Metoprolol Succinate Extended Release 25 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented extended-release formulation Controlled-release tablet manufacturing technology Blister and Alu-Alu packaging options OLMEROOT-MT 25 from DIABGLYM combines effective blood pressure control, sustained heart rate management, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Olmesartan and Metoprolol formulation.

OLMEROOT Olmesartan Medoxomil 40 mg Tablets Division: DIABGLYM Composition Each tablet contains: Olmesartan Medoxomil IP — 40 mg Excipients — q.s. Colour: Approved colour used Dosage form: Oral tablet Product Description OLMEROOT contains Olmesartan Medoxomil 40 mg, a potent angiotensin II receptor blocker (ARB) formulated for the effective management of hypertension and long-term cardiovascular and renal protection. Olmesartan provides sustained blood pressure control by selectively blocking the angiotensin II AT1 receptor, resulting in vasodilation, reduced peripheral vascular resistance, and decreased aldosterone-mediated sodium retention. Olmesartan Medoxomil is widely prescribed in cardiology, nephrology, and internal medicine for patients with essential hypertension, diabetes-associated hypertension, chronic kidney disease, metabolic syndrome, and high cardiovascular risk. It helps reduce systolic and diastolic blood pressure, improve vascular function, and lower the risk of stroke, myocardial infarction, heart failure, and progressive renal damage. OLMEROOT is particularly beneficial for patients requiring intensive blood pressure control, once-daily antihypertensive therapy, and comprehensive cardiovascular and renal protection. Technical Knowledge of Olmesartan Medoxomil Olmesartan Medoxomil is a prodrug that is rapidly converted to the active metabolite Olmesartan after oral administration. Olmesartan selectively blocks angiotensin II type 1 (AT1) receptors, preventing angiotensin II-mediated vasoconstriction, aldosterone secretion, sympathetic activation, and vascular remodeling. Unlike ACE inhibitors, ARBs do not inhibit bradykinin metabolism, which contributes to a lower incidence of cough and angioedema. Olmesartan has a long duration of action, allowing effective once-daily dosing and sustained 24-hour blood pressure control. Mechanism of Action Olmesartan selectively blocks AT1 receptors, prevents angiotensin II-mediated vasoconstriction, reduces aldosterone secretion, decreases peripheral vascular resistance, lowers blood pressure, improves vascular compliance, and provides cardiovascular and renal protection. Key Benefits Effective reduction of systolic and diastolic blood pressure Provides sustained 24-hour blood pressure control Supports cardiovascular and renal protection Improves vascular function and endothelial health Reduces arterial stiffness Helps prevent stroke and myocardial infarction Suitable for diabetic and chronic kidney disease patients Convenient once-daily dosing Suitable for long-term hypertension management under medical supervision Clinical Applications OLMEROOT is commonly prescribed for essential hypertension, uncontrolled hypertension, hypertension with diabetes mellitus, hypertension with chronic kidney disease, metabolic syndrome, cardiovascular risk reduction, diabetic nephropathy, and long-term antihypertensive management. Facts About Olmesartan Medoxomil Olmesartan is a highly selective ARB with strong antihypertensive efficacy and extensive clinical evidence supporting cardiovascular and renal protection. It is widely recommended in international hypertension guidelines and is particularly valuable in patients with diabetes, chronic kidney disease, and high cardiovascular risk because of its excellent blood pressure control and target organ protective effects. Key Facts Potent angiotensin II receptor blocker (ARB) Olmesartan Medoxomil 40 mg for intensive blood pressure control Provides sustained 24-hour antihypertensive action Supports cardiovascular and renal protection Effective in diabetic and chronic kidney disease patients Evidence-based ARB therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity OLMEROOT is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, chronic kidney disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this formulation. Why Choose OLMEROOT for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Olmesartan Medoxomil 40 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented formulation Moisture-controlled tablet manufacturing Blister and Alu-Alu packaging options OLMEROOT from DIABGLYM combines effective blood pressure control, comprehensive cardiovascular and renal protection, evidence-based ARB therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Olmesartan formulation.

PRASUROOT-10 Prasugrel Hydrochloride 10 mg Tablets Division: DIABGLYM Composition Each tablet contains: Prasugrel Hydrochloride IP equivalent to Prasugrel — 10 mg Excipients — q.s. Colour: Approved colour used Dosage form: Oral tablet Product Description PRASUROOT-10 contains Prasugrel Hydrochloride 10 mg, a potent third-generation antiplatelet agent formulated for the prevention of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS), coronary artery disease, and post-percutaneous coronary intervention (PCI). Prasugrel provides rapid, potent, and consistent platelet inhibition, significantly reducing the risk of myocardial infarction, stent thrombosis, ischemic stroke, and recurrent cardiovascular events. Prasugrel is widely prescribed in cardiology for patients with ST-elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI), unstable angina, coronary stenting, and high-risk ischemic cardiovascular disease. It is commonly used as part of dual antiplatelet therapy (DAPT) in combination with aspirin for long-term secondary prevention of cardiovascular events. PRASUROOT-10 is particularly beneficial for patients undergoing PCI, post-coronary stenting, acute coronary syndrome, diabetes-associated coronary artery disease, and individuals requiring intensive and sustained platelet inhibition. Technical Knowledge of Prasugrel Prasugrel is a prodrug that undergoes rapid hepatic activation to form an active metabolite that irreversibly inhibits the platelet P2Y12 ADP receptor. This blocks ADP-mediated activation of the GPIIb/IIIa receptor complex, resulting in potent inhibition of platelet aggregation and arterial thrombus formation. Prasugrel produces rapid onset of action, consistent platelet inhibition, and lower interpatient variability compared with several earlier P2Y12 inhibitors. Its irreversible receptor inhibition provides sustained antiplatelet activity for the lifespan of affected platelets. Mechanism of Action Prasugrel irreversibly inhibits the platelet P2Y12 ADP receptor, blocks ADP-mediated platelet activation, prevents GPIIb/IIIa receptor activation, inhibits platelet aggregation, and reduces arterial thrombus formation. Key Benefits Potent and rapid platelet inhibition Reduces the risk of myocardial infarction Helps prevent stent thrombosis Reduces recurrent ischemic cardiovascular events Provides consistent antiplatelet efficacy Effective in acute coronary syndrome Supports long-term secondary cardiovascular prevention Suitable for post-PCI antiplatelet management under medical supervision Clinical Applications PRASUROOT-10 is commonly prescribed for acute coronary syndrome, post-percutaneous coronary intervention, post-coronary stenting, STEMI, NSTEMI, unstable angina, coronary artery disease, diabetic cardiovascular disease, and secondary prevention of recurrent cardiovascular events. Facts About Prasugrel Prasugrel is a highly effective P2Y12 receptor inhibitor with extensive clinical evidence supporting reduction of ischemic events and stent thrombosis in ACS patients undergoing PCI. It provides rapid and consistent platelet inhibition and is recommended in major international cardiology guidelines for appropriate patients with acute coronary syndrome treated with coronary intervention. Key Facts Third-generation P2Y12 receptor inhibitor Prasugrel 10 mg for potent antiplatelet therapy Rapid and sustained platelet inhibition Reduces stent thrombosis and recurrent ischemic events Essential therapy after PCI and acute coronary syndrome Evidence-based cardiovascular antiplatelet therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity PRASUROOT-10 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of coronary artery disease, acute coronary syndrome, diabetes, hypertension, and coronary interventions creates strong prescription demand and long-term market potential for this formulation. Why Choose PRASUROOT-10 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Prasugrel Hydrochloride 10 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented formulation Moisture-controlled tablet manufacturing Blister and Alu-Alu packaging options PRASUROOT-10 from DIABGLYM combines potent antiplatelet protection, evidence-based cardiovascular therapy, comprehensive thrombotic risk reduction, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Prasugrel formulation.

PRASUROOT-AP 10/75 Prasugrel 10 mg and Aspirin 75 mg Tablets Division: DIABGLYM Composition Each tablet contains: Prasugrel Hydrochloride IP equivalent to Prasugrel — 10 mg Aspirin IP — 75 mg Excipients — q.s. Colour: Approved colour used Dosage form: Oral tablet Product Description PRASUROOT-AP 10/75 is a potent dual antiplatelet therapy (DAPT) combination containing Prasugrel 10 mg and Aspirin 75 mg, formulated for the prevention of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS), post-percutaneous coronary intervention (PCI), and coronary artery disease. This combination provides comprehensive platelet inhibition, significantly reducing the risk of myocardial infarction, stent thrombosis, ischemic stroke, and recurrent cardiovascular events. Prasugrel is a third-generation P2Y12 receptor inhibitor that provides rapid, potent, and consistent platelet inhibition, while Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1), reducing thromboxane A2 synthesis and platelet aggregation. Together, they offer superior protection against arterial thrombosis in high-risk cardiovascular patients. PRASUROOT-AP 10/75 is particularly beneficial for patients with acute coronary syndrome undergoing PCI, post-coronary stenting, ST-elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI), unstable angina, diabetes-associated coronary artery disease, and patients requiring long-term secondary prevention of cardiovascular events. Technical Knowledge of Prasugrel and Aspirin Prasugrel is a prodrug that undergoes rapid hepatic activation to form an active metabolite that irreversibly inhibits the platelet P2Y12 ADP receptor. This prevents ADP-mediated activation of the GPIIb/IIIa receptor complex, resulting in potent inhibition of platelet aggregation. Aspirin irreversibly acetylates cyclooxygenase-1 (COX-1) in platelets, inhibiting thromboxane A2 production and suppressing platelet activation for the lifespan of circulating platelets. The combination of Prasugrel and Aspirin targets two distinct pathways of platelet activation, providing enhanced antithrombotic efficacy and reducing the risk of arterial thrombotic complications. Mechanism of Action Prasugrel irreversibly inhibits the platelet P2Y12 receptor, blocks ADP-mediated platelet activation, prevents GPIIb/IIIa activation, and reduces platelet aggregation. Aspirin irreversibly inhibits COX-1, suppresses thromboxane A2 synthesis, reduces platelet activation, and provides sustained antiplatelet protection. Key Benefits Potent dual antiplatelet therapy Reduces the risk of myocardial infarction Prevents stent thrombosis Reduces recurrent ischemic cardiovascular events Provides rapid and sustained platelet inhibition Effective in acute coronary syndrome Supports long-term secondary cardiovascular prevention Suitable for post-PCI antiplatelet management under medical supervision Clinical Applications PRASUROOT-AP 10/75 is commonly prescribed for acute coronary syndrome, post-percutaneous coronary intervention, post-coronary stenting, STEMI, NSTEMI, unstable angina, coronary artery disease, diabetic cardiovascular disease, and secondary prevention of recurrent cardiovascular events. Facts About Prasugrel and Aspirin Prasugrel provides more potent and consistent platelet inhibition than several earlier P2Y12 inhibitors and has strong clinical evidence supporting reduction of ischemic events in ACS patients undergoing PCI. Aspirin remains the cornerstone of antiplatelet therapy for cardiovascular disease. Their combination is recommended in major international cardiology guidelines for appropriate patients following acute coronary syndromes and coronary intervention. Key Facts Dual antiplatelet therapy (DAPT) Prasugrel 10 mg for potent P2Y12 inhibition Aspirin 75 mg for COX-1 inhibition Reduces stent thrombosis and recurrent ischemic events Essential therapy after PCI and acute coronary syndrome Evidence-based cardiovascular combination therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity PRASUROOT-AP 10/75 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of coronary artery disease, acute coronary syndrome, diabetes, hypertension, and coronary interventions creates strong prescription demand and long-term market potential for this combination. Why Choose PRASUROOT-AP 10/75 for PCD Pharma Franchise? High prescription potential Strong physician and cardiologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Prasugrel 10 mg and Aspirin 75 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented formulation Moisture-controlled tablet manufacturing Blister and Alu-Alu packaging options PRASUROOT-AP 10/75 from DIABGLYM combines potent dual antiplatelet protection, evidence-based cardiovascular therapy, comprehensive thrombotic risk reduction, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Prasugrel and Aspirin formulation.